ANALOGS OF EPOTHILONE

Specification

Cross-Reference to Related Applications:

This is a nonprovisional application claiming priority from and is a continuation-in-
5   part application of provisional US patent application Serial No. 60/400,535, filed August 2,
2002 and of provisional US patent application, filed June 24, 2003, Serial No. unknown
(Express Mail Number EV331243442US).

Technical Field:

10   The invention relates to antitumor agents. More particularly, the invention related
to analogs of epothilone as antitumor agents.

Background:

The epothilones e.g. **1** (A) and **2** (B), Figure 1B, are a class of molecules having
15   potent cytotoxicity against tumor cells, including Taxol™ (paclitaxel) resistant cell lines.
Within this class, it has been observed that cyclopropane- and pyridine- containing
analogs of epothilones B and compound **106** exhibit outstanding biological profiles as
potential antitumor agents.   Herein are disclosed designed analogs of epothilone B
characterized by such structural motifs, but having enhanced cytotoxicity against tumor
20   cells and/or enhanced biological profiles as potential antitumor agents.

Summary:

Disclosed herein are a number of rationally designed epoxide and cyclopropane
epothilone B analogs with substituted side-chains. These analogs have been evaluated
25   with respect to their biological activities against a series of human cancer cell lines.
Among the several bioactive analogs, the novel cyclopropyl epothilone B analog **104** with
a thiomethyl thiazole ring stands out as the most potent. This compound is 6-fold more
active than the naturally occurring epothilone B (**2**) and appears to be, together with its
oxygen counterpart **3**, the most potent epothilone B analog synthesized to date.
30   Previous structure-activity relationship studies (Nicolaou, K. C.; et al. *Chem. Commun.*
2001, 1523–1535; Nicolaou, K. C.; et al. *ChemBioChem.* **2001**, *2*, 69–75; Nicolaou, K.
C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432.) together with the data presented herein
reconfirm that the epoxide oxygen is not required for biological activity within this class of
small molecules and that the lipophilic thiomethyl group on the thiazole moiety enhances

considerably the potency of these compounds. Lacking the relatively reactive epoxide moieties of **2** and **3**, epothilone **104** may be endowed with certain advantages over the former compounds with regards to stability and side effects and, therefore, it may present a unique opportunity for clinical development.

5   The invention is directed to analogs of epothilone having potent cytotoxic active against a variety of cell lines, including Taxol®-resistant tumor cells. Another aspect of the invention is directed to the use of such compounds as cytotoxic agents.

One aspect of the invention is directed to a compound represented by formula I:


                                                                          I

15   In Formula I, R is a radical selected from the group consisting of the following structures:

20

Preferred embodiments of this aspect of the invention include compounds represented by the following formulae:

25

30

35

5

; and

Another aspect of the invention is directed to a compound represented by formula II:

10

II

15   In formula II, R is a radical selected from the group consisting of the following structures:

; and

Preferred embodiments of this aspect of the invention are represented by the following

20   formula:

25

and

Another aspect of the invention is directed to a pharmaceutical composition containing a therapeutic dose of a compound within either formula I or formula II,

30   represented above, for the treatment of a proliferative disease in a mammal.   In a preferred mode, the mammal is a human.

Another aspect of the invention is directed to a compound represented by the following structure:

35

5

In the above structure, R is a radical selected from the group consisting of radicals
10 represented by the following structures:

15

20 Preferred embodiments of this aspect of the invention include compound represented by
the following structures:

25

30

35

;

; and

Another aspect of the invention is directed to a compound represented by the following structure:

In the above structure, R is a radical selected from group consisting of -Me, -Cl, -Br, -SMe, and -CF$_3$.   Preferred embodiments of this aspect of the invention include compounds represented by the following structures:

5

;

10

;

15

20

;

25

; and

30

.

35

Other aspects of the invention are directed to compounds represented by the following structures:

5

; and

10

15

Another aspect of the invention is directed to a compound represented by the following structure:

20

25   Another aspect of the invention is directed to a compound represented by the following structure:

30

Brief Description of Drawings:

Figure 1A illustrates the structures of selected natural and designed epothilones. Grey boxes indicate compounds synthesized in this study.

Figure 1B illustrates a series of structures of the various designed analogs of epothilones A and B along with the structures of epothilone A and B.

Figure 2 illustrates a chart disclosing the displacement of the fluorescent taxoid Flutax-2 (50 nM) from microtubule binding sites (50 nM) by competing ligands at 37 °C.

Figure 3 illustrates the synthesis of 2-(thiomethyl)thiazole epothilone B (3) via Stille coupling.

Figure 4 illustrates a retrosynthetic analysis of trans-cyclopropyl epothilone B analogues (1 - 6, 8, 10, and 12–14).

Figure 5 illustrates the construction of aldehyde 32.

Figure 6 illustrates the construction of vinyl iodides 20c–g.

Figure 7 illustrates the synthesis of epothilone analogues 8–14.

Figure 8 is a scheme showing the last step in the synthesis of many of the analogs from the vinyl iodide 15.

Figure 9 illustrates a scheme showing the steps required to synthesize the stannanes used in the scheme in Figure 8.

Figure 10 illustrates a scheme showing the synthetic route taken to build the skeleton of the cyclopropyl analogs of epothilone B.

Figure 11 illustrates a scheme showing the final steps used in the synthesis of cyclopropyl analogs 104 and 106.

Figure 12 illustrates a table with the cytotoxicities of epothilones 104, 106 and 107-116 against human carcinoma cells and β-tubulin mutant cell lines selected with paclitaxel or epothilone A.

Figure 13 illustrates a table with the cytotoxicities (IC_{50}'s in nM) of selected epothilones against the human epidermoid cell lines KB-3 and KB-8511.

Figure 14 illustrates a table disclosing the cytotoxicity of epothilones 1 through 14 and paclitaxel against 1A9 human ovarian carcinoma cells and β-tubulin mutant cell lines selected with paclitaxel or epothilone A.

Figure 15 illustrates a table disclosing the tubulin polymerization potency and cytotoxicity of epothilones 1–8, 10–14, and paclitaxel against human epidermoid cancer cell lines.

Figure 16 illustrates a table disclosing binding affinities of epothilone analogues to the taxoid binding site of microtubules.

Detailed Description

The construction of a series of epoxide and cyclopropane epothilones with varying side chains by chemical synthesis and biologically evaluated is disclosed. The biological
5   evaluation of these compounds led to the identification of the thiomethylthiazole side chain as a desirable pharmacophoric group improving the biological activity of the epothilones with regard to cytotoxicity and tubulin polymerizing properties. The enhanced activity was confirmed by three distinct biological assays where the effects of the compounds tested were determined both in cells and *in vitro.*
10

Design and chemical synthesis of epothilone analogues:

As an initial foray, we decided to confirm the potency enhancement bestowed on the epothilone scaffold by the methylthio group as compared to the methyl substituent in the epothilone B series. The methylthiothiazole epothilone B (**3**) was thus synthesized by
15   Stille coupling of stannane **16** (Nicolaou, K. C.; et al. *Bioorg. Med. Chem.* **1999**, 7, 665-697) with vinyl iodide **15** (Nicolaou, K. C.; et al. *Chem. Eur. J.* **2000**, 6, 2783-2800) (80% yield) as shown in Figure 3. The observed high potency of analogue **3** against a series of tumor cell lines (see Table 1) encouraged us to proceed with the design and synthesis of an entire family of methylthio analogues as well as a number of new
20   pyridine-containing epothilones.

Figure 4 outlines, in retrosynthetic format, the pathway that was followed for the construction of the designed epothilone B analogues. Based on our previously reported strategy, the adopted sequence required a Charette cyclopropanation reaction (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, 123, 9313-9323; Charette, A. B.; et al. *J. Am.*
25   *Chem. Soc.* **1998**, 120, 11943-11952) to establish early on in the synthesis the 12,13-cyclopropyl site, an aldol reaction according to our optimized procedure (Nicolaou, K. C.; et al. *Chem. Eur. J.* **2000**, 6, 2783-2800) to construct the C6-C7 bond with its two stereocenters, a Nozaki-Hiyama-Kishi coupling (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, 123, 9313-9323; Takai, K.; et al. *Tetrahedron Lett.* **1983**, 24, 5281-5284;
30   Jin, H.; et al. *J. Am. Chem. Soc.* **1986**, 108, 5644-5646) to introduce the side chain, and a Yamaguchi macrolactonizaion (Inanaga, J.; et al. *Bull. Chem. Soc. Jpn.* **1979**, 52, 1989-1993; Mulzer, J.; et al. *Synthesis* **1992**, 215-228; Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **1997**, 119, 7974-7991) to complete the macrocyclic structure. Key building blocks **18**, **19**, and **20** were thus defined as the starting points for these constructions.
35   Construction of the corresponding epothilone A analogues was envisaged to be carried

out in the same manner as previously reported by us (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, *123*, 9313-9323).

Scheme 3 outlines the synthesis of the required aldehyde **32** from the readily available geraniol (**18**). Thus, Charette cyclopropanation of **18** (Et_2Zn-CH_2I_2, in the presence of chiral ligand **21**) (Charette, A. B.; et al. *J. Am. Chem. Soc.* **1998**, *120*, 11943-11952) furnished cyclopropyl alcohol **22** in 87% yield and 93% ee. Protection of the hydroxy group in **22** (NaH-BnBr) (for abbreviations of reagents and protecting groups, see legends in schemes) followed by ozonolysis (O_3; $NaBH_4$) of the remaining double bond led to compound **23** in 89% overall yield. Conversion of alcohol **23** to the corresponding iodide (**24**, 95% yield) was accomplished upon mesylation and subsequent reaction with NaI. Alkylation of (–)-propionaldehyde SAMP hydrazone (**25**) (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **1997**, *119*, 7974-7991; Enders, D. *Aymmetric Synth.* **1984**, *3*, 275-339; Enders, D.; Klatt, M. *Synthesis* **1996**, 1403-1418) with iodide **24** under the influence of LDA gave compound **26** (84% yield), whose cleavage (MeI; HCl_{aq}) led to aldehyde **17** in 86% yield. The ratio of the resulting C-8 epimers was determined to be *ca.* 97:3 by ^{1}H NMR analysis of the MTPA esters derived from aldehyde **17** (Tsuda, M.; Endo, T.; Kobayashi, J. *J. Org. Chem.* **2000**, *65*, 1349-1352 and references cited therein). The aldol condensation between ketone **19** and aldehyde **17** under the previously defined conditions [LDA (2.4 equiv), ketone **19** (2.3 equiv), –78 to –40 °C, 30 min; then aldehyde **17**, –78 °C, 5 min] (Nicolaou, K. C.; et al. *Chem. Eur. J.* **2000**, *6*, 2783-2800) afforded aldol product **27** which was isolated in a diastereomerically pure form (81% yield). Subsequent protection of the secondary alcohol in **27** as a TBS ether (TBSOTf, 2,6-lutidine) followed by selective cleavage of the primary TBS group (HF•py) afforded, in 88% overall yield, alcohol **28**. The latter compound was stepwise oxidized to the carboxylic acid (DMP; then $NaClO_2$) which was then protected as the TMSE ester **29** (TMSE-OH, EDC, 4-DMAP) in 75% overall yield. Hydrogenolysis of the benzyl ether in **29** followed by oxidation with DMP led to aldehyde **30** (84% yield) whose homologation ($NaHMDS$-$MeOCH_2PPh_3Cl$; then PPTS) to the coveted higher aldehyde **32** proceeded smoothly, and via vinyl ether **31** (*ca.* 1:1 *E:Z* ratio), with 82% overall yield.

The side chains (**20a–g**, Scheme 4) were synthesized either as previously reported (**20a** and **20b**) (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, *123*, 9313-9323) or from the corresponding aryl halides (**33** (Ellingboe, J. W.; et al. *J. Med. Chem.* **1994**, *37*, 542-550), **37**, **38**, **39**) as shown in Scheme 4. Protection of 4-hydroxymethyl-2-pyridyl bromide **33** as a trityl ether (TrCl, 4-DMAP, 100%) followed by Sonogashira coupling (Arcadi, A.; et al. *Tetrahedron* **1994**, *50*, 437-452) of the resulting

aryl bromide **34** with propyne [Pd(PPh$_3$)$_2$Cl$_2$-CuI, 96%] led to acetylenic compound **35** which served as a precursor to vinyl iodide **20c** (*n*-BuLi; then (*n*-Bu$_3$Sn)$_2$, CuCN, MeOH; then I$_2$, 80% yield). Exchange of the trityl for a MOM group within **35** [HCl(g), CHCl$_3$; then NaH, MOM-Cl, 34% overall yield] (Betzer, J.-F.; et al. *Tetrahedron Lett.* **1997**, *38*, 2279-2282) allowed access to vinyl iodide **20d** (67% yield) by exposure of the resulting intermediate **36** to the same conditions described above for the **35** to **20c** conversion. Similar chemistry was employed to construct vinyl iodides **20e–20g** from **37–39**, respectively, as shown in Scheme 4.

Two crucial bond formations and two accompanying deprotections separated key building blocks **32** (prepared in this study for epothilone B analogues), **40** (prepared as previously described for epothilone A analogues) (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, *123*, 9313-9323), and **20a–g** (for side chains) from the targeted epothilone analogues. The first operation was the Nozaki-Hiyama-Kishi coupling (Takai, K.; et al. *Tetrahedron Lett.* **1983**, *24*, 5281-5284; Jin, H.; et al. *J. Am. Chem. Soc.* **1986**, *108*, 5644-5646) of aldehydes **32** and **40** with vinyl iodides **20a–g**. This carbon-carbon bond forming reaction worked admirably in this instance (CrCl$_2$, NiCl$_2$, 4-*t*-BuPy, DMSO), furnishing, after TBAF-induced carboxylic acid generation, coupling products (**41a**, **41b**, **41d–g**, **42c and 42e**) in yields indicated in Scheme 5 (as *ca.* 1:1 mixtures of C-15 diastereomers). Each mixture of hydroxy acid diastereomers (**41a**, **41b**, **41d–g**, **42c and 42e**) was then subjected to Yamaguchi macrocyclization (2,4,6-trichlorobenzoyl chloride, 4-DMAP) to afford the desired 15(*S*) lactone in the indicated (unoptimized) yields together with its 15(*R*) epimer. The separation of the two epimers at this juncture was facilitated by their rather drastically different R$_f$ values on silica gel. Final deprotection of protected derivatives either with 20% TFA in CH$_2$Cl$_2$ (**43a**, **43b**, **43e–g**, **44c and 44e**) or with TMSBr-4Å MS in CH$_2$Cl$_2$, followed by 20% TFA in CH$_2$Cl$_2$ (**43d**), led to epothilones **6**, **8–14** in the indicated (unoptimized) yields (Scheme 5). Chromatographically and spectroscopically pure compounds were subjected to biological evaluations as described below.

Chemical biology:

The biological activities of the synthesized epothilones were evaluated through cytotoxicity, *in vitro* tubulin polymerization, and tubulin binding assays. Cytotoxicity was first evaluated in a set of ovarian carcinoma cell lines, including a parental cell line (1A9) and three drug-resistant cell lines, namely the paclitaxel-resistant strains (Giannakakou, P.; et al. *J. Biol. Chem.* **1997**, *272*, 17118-17125) 1A9/PTX10 and 1A9/PTX22 and the

epothilone-resistant strain (Giannakakou, P.; et al. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 2904-2909) 1A9/A8. These resistant cell lines harbor distinct acquired β-tubulin mutations which affect drug-tubulin interaction and result in impaired taxane and epothilone-driven tubulin polymerization. The results of these biological investigations
5   are summarized in Table 1 (Skehan, P.; et al. *J. Natl. Cancer Inst.* **1990**, *82*, 1107-1112). Further cytotoxicity and *in vitro* tubulin polymerization assays were carried out using a set of human epidermoid cancer cell lines, including a parent cell line (KB-31) and a paclitaxel-resistant (due to Pgp overexpression) cell line (KB-8511). The results of these studies are summarized in Table 2 (Nicolaou, K. C.; et al. *Chem. Biol.* **2000**, *7*,
10   593-599; Meyer, T.; et al. *Int. J. Cancer* **1989**, *43*, 851-856).

In general, there is good agreement between the *in vitro* tubulin polymerization potency and the cytotoxicity profile of the tested compounds against both the 1A9 human ovarian carcinoma cells and the KB-31 human epidermoid carcinoma cells. In agreement with original observations with the naturally occurring epothilones A and B,
15   none of the epothilone A or B analogues tested herein appears to be a good substrate for the drug-efflux pump P-glycoprotein (Pgp). This is evident by the lack of cross-resistance of each of these analogues to the Pgp expressing cell line KB-8511, in contrast to paclitaxel-a known Pgp substrate- which is 214-fold less active against KB-8511 cells (see Table 2). It is noteworthy that all the epothilone analogues appear more active
20   against the β-tubulin mutants compared to epothilone A (**1**) and epothilone B (**2**) (see Table 1, RR values). This is more pronounced with compounds **10–14** for which the relative resistance values (RR) range from 1.6–7.8 against PTX10 (β270) and A8 (β274) cells compared with 9.4-24.9 RR values for Epo A (**1**) and Epo B (**2**). Furthermore, in the current study, and in agreement with previous reports (Nicolaou, K. C.; et al.
25   *ChemBioChem* **2001**, *2*, 69-75; Giannakakou, P.; et al. *J. Biol. Chem.* **1997**, *272*, 17118-17125; Giannakakou, P.; et al. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 2904-2909), we found that the paclitaxel-selected mutant PTX22 (β364) retains almost full sensitivity to the epothilones, and to all epothilone analogues tested in this report (RR values ≤ 3.3).
30

In addition to the above biological assays, the relative potency of each epothilone analogue was measured by the fluorescent taxoid displacement assay (Andreu, J. M.; Barasoain, I. *Biochemistry* **2001**, *40*, 11975-11984). The purpose of these experiments was to compare the equilibrium constants with which microtubules bind at their taxane
35   site the epothilone analogues investigated. The inhibition of the binding of the

well-characterized fluorescent taxoid Flutax-2 (Souto, A. A.; et al. *Angew. Chem. Int. Ed. Engl.* **1995**, *34*, 2710-2712; Díaz, J. F.; et al. *J. Biol. Chem.* **2000**, *275*, 26265-26276; Abal, M.; et al. *Cell. Motil. Cytoskeleton* **2001**, *49*, 1-15) to microtubules by each of the epothilone analogues was measured at 37 °C (Figure 2). The resulting equilibrium

5   dissociation constants shown in Table 3 indicate that epothilone A (**1**) has the lowest binding affinity among the epothilone analogues tested (Kd = 34±4). The most powerful ligand among those measured in this assay is compound **3**, with a Kd value of 0.64±0.24 nM, followed by compounds **8**, **11–13**, with similar Kd values comprised between 1.6 and 1.9 nM. With the possible exception of compound **13**, the binding affinities of the

10   analogues tested mirror their respective activities in both cell growth inhibition and *in vitro* tubulin polymerization assays.

Collectively from all three biological assays employed herein, a number of conclusions can be drawn in terms of structure-activity relationships within the epothilone family. First, the addition of the C12 methyl group does not enhance the activity in the

15   *trans*-cyclopropyl series (compound **5** *vs* **6**, **7** *vs* **8**, **9** *vs* **10**), contrary to the result in the *cis* epoxide series, where epothilone B (**2**) is at least 10-fold more active than epothilone A (**1**). This could be due to the different orientation of the C12 methyl group in the *cis* and *trans* compounds or to overall differences in conformation between the *cis* and *trans* compounds, although the details remain to be elucidated. Second, the introduction of the

20   2-thiomethylthiazole side chain enhances the activity compared with the natural 2-methylthiazole side chain (compounds **2** *vs* **3**, **5** *vs* **11**, and **6** *vs* **12**). This effect was previously observed for epothilone C and D analogues (Nicolaou, K. C.; et al. *Angew. Chem.* **1997**, *109*, 2181-2187; *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 2097-2103; see also: Sinha, S. C.; et al. *ChemBioChem* **2001**, *2*, 656-665). Third, the replacement of a

25   methyl group with a thiomethyl group in the pyridine side chain series (compounds **8** *vs* **13**) reduces potency, contrary to the results obtained for the thiazole side chains above. This conclusion was based on the cell cytotoxicity and *in vitro* tubulin polymerization data, while in the fluorescent taxoid displacement assay the replacement of the methyl group with a thiomethyl moiety in the pyridine side chain is indifferent in terms of binding affinity.

30   This discrepancy may simply reflect differences in cell uptake and permeability of the compounds tested or differences in the sensitivity of the two tubulin assays. Despite this discrepancy, it is clear from these data that the introduction of a thiomethyl group at the thiazole side chain is a more favorable modification than the introduction of a thiomethyl group at the pyridine side chain, which may be due to differing steric requirements by the

35   two side chain scaffolds. In agreement with previous data obtained with *cis* pyridine

epothilone analogues (Nicolaou, K. C.; et al. *Chem. Biol.* **2000**, *7*, 593-599), relocation of the thiomethyl group of the pyridine side chain from the position 5 (compound **13**) to position 6 (compound **14**) resulted in significant loss of activity. Fourth, mixed results are obtained with compounds **7** *vs* **9** and **8** *vs* **10** in which the 5-methylpyridine side chain

5   (compounds **7** and **8**) is substituted by the 5-hydroxymethylpyridine side chain (compounds **9** and **10**). This substitution appears indifferent in cytotoxicity assays against the 1A9 human ovarian carcinoma cells (Table 1) where very similar IC_{50} values are obtained for each pair (e.g. 0.6 and 0.7 nM for compounds **7** and **9**, respectively; 1.7 nM for compounds **8** and **10**). On the other hand, in the human epidermoid carcinoma

10   cells KB-31, compound **10** is 2-fold more active than its counterpart compound **8** with IC_{50}s at 0.44 *vs* 0.9 nM, respectively. Given the small differences in the growth rate of the two human cancer cell lines that could account for the differential results, we could conclude that the introduction of the 5-hydroxymethylpyridine side chain is not likely to enhance activity in, at least, *trans*-12,13-cyclopropyl analogues of the epothilone family.

15

Design of further analogs:

The design of a further epothilone library was based on the current knowledge of structure activity relationships (SAR), specifically the facts that: (1) epothilone B (**2**) is considerably more potent than epothilone A (**1**); (2) a thiomethyl replacement for the

20   methyl group on the thiazole moiety enhances the potency (Nicolaou, K. C.; et al. *Angew. Chem.* **1998**, *110*, 2120–2153; *Angew. Chem. Int. Ed.* **1998**, *37*, 2014–2045. Nicolaou, K. C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432; Nicolaou, K. C.; et al. *Angew. Chem.* **1998**, *110*, 89–92; *Angew. Chem. Int. Ed.* **1998**, *37*, 84–87.); (3) a heterocycle such as pyridine (Nicolaou, K. C.; et al. *Chem. Biol.* **2000**, *7*, 593–599.) replacement for

25   the thiazole ring needs to maintain the proper position for the nitrogen for biological activity; and (4) a cyclopropane ring can replace the epoxide moiety without loss of activity (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, *123*, 9313–9323; Nicolaou, K. C.; et al. *ChemBioChem.* **2001**, 2, 69–75; Johnson, J. A.; et al. *Org. Lett.* **2000**, *2*, 1537–1540.). From these considerations, epothilones **104**, **106** and **107–116** (Figure 1B)

30   were considered as prime candidates for chemical synthesis and biological evaluation.

The designed epothilone analogs (**107–116**) were synthesized in a convergent manner from vinyl iodide **15** (Nicolaou, K. C.; et al. *Chem. Eur. J.* **2000**, *6*, 2783–2800.) and the corresponding aromatic stannanes as shown in Figure 8 (for abbreviations of

35   reagents and protective groups, see the detailed description of figures). Thus, a

Stille-type coupling of **15** with appropriate stannanes (**120a–d**, **122a–d**, **123** and **124**) was carried out in the presence of PdCl$_2$(MeCN)$_2$, CuI and AsPh$_3$ in DMF at ambient temperature, leading directly to the desired epothilones (**107–116**) in the indicated yields. The required aromatic stannanes were prepared as summarized in Figure 9. Thus, for the thiazole compounds **120a–120d**, the commercially available 2,4-dibromothiazole (**118**) was reacted with the corresponding thiol in the presence of NaH leading first to the intermediate sulfides (**119a–119d**) through replacement of the more reactive 2-bromide substituent. Subsequent coupling of these substrates with Me$_3$SnSnMe$_3$ in the presence of Pd(PPh$_3$)$_4$ in toluene at 100 °C then gave the desired products **120a–120d** via reaction of the second bromide residue. The pyridyl stannanes **122a–122d** were similarly synthesized from the readily available 2-bromopyridines **121a**, **121b** (Virgilio, N. *J. Org. Chem.* **1973**, *38*, 2660–2664), **38** (Nicolaou, K. C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432) and **39** (Testaferri, L.; et al. *Tetrahedron* **1985**, *41*, 1373–1384) via metal-halogen exchange (*n*BuLi) followed by quenching of the resulting 2-lithioderivatives (Gilman, H.; et al. *J. Org. Chem.* **1951**, *16*, 1788–1791) with *n*Bu$_3$SnCl. Stannanes **123** (Dinnell, K.; et al. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1237–1240) and **124** (Jessie, S.; Kjell, U. *Tetrahedron* **1994**, *50*, 275–284) were prepared according to the corresponding literature procedures from the respective halides.

The chemical synthesis of cyclopropane epothilones **104** and **106** required the key aldehyde **139** which was constructed from nerol (**125**) as shown in Figure 10. Thus, Charrette asymmetric cyclopropanation (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, *123*, 9313–9323; Nicolaou, K. C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432; Charette, A. B.; et al. *J. Am. Chem. Soc.* **1998**, *120*, 11943–11952.) of **125** in the presence of ligand **21** according to the literature, furnished cyclopropane alcohol **127** in 80 % yield and 95 % ee. The hydroxyl group in **127** was protected as benzyl ether (NaH, BnBr, 100 %) and the resulting product was subjected to ozonolysis (O$_3$, NaBH$_4$) leading to primary alcohol **128** (83 % yield). This alcohol was converted to the corresponding iodide (**129**) via mesylation (MsCl, Et$_3$N) and subsequent displacement of the intermediate mesylate with NaI (91 % overall). Ender's alkylation (Enders, D. *Asymm. Synth.* **1984**, *3*, 275–339; Enders, D.; Klatt, M. *Synthesis* **1996**, 1403–1418.) of (–)-SAMP hydrazone **25** with iodide **129** under the influence of LDA proceeded smoothly to afford hydrazone **131** (87 % yield), whose cleavage (MeI; HCl aq) led to aldehyde **132** (91 % yield). The crucial aldol reaction between ketone **19** (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **1997**, *119*, 7974–7991.) (LDA) and aldehyde **132** proceeded smoothly and stereoselectively in

THF:ether (1:1) at −78 °C to afford the desired hydroxy ketone **134** in 80 % yield. Protection of the secondary alcohol in **134** as a silyl ether (TBSOTf, 2,6-lutidine) followed by selective removal of the primary TBS group (HF•py) furnished primary alcohol **135** (86 % overall yield). The later compound (**135**) was then oxidized stepwise [(COCl)$_2$, DMSO,

5   −78 °C; NaClO$_2$)] and the resulting carboxylic acid was protected as a TMSE ester (TMSE-OH, EDC, DMAP, 73 % overall yield) to afford **136**. Hydrogenolysis of the benzyl group within **136** [H$_2$, 10 % Pd(OH)$_2$/C, 89 % yield] led to alcohol **137**, whose Swern oxidation [(COCl)$_2$, DMSO, Et$_3$N] led to the corresponding aldehyde **138** (99 % yield). Homologation of this aldehyde (**138**) via Wittig olefination (MeOCH$_2$P$^+$Ph$_3$Cl$^-$, nBuLi, 79

10   % yield) followed by acid hydrolysis (PPTS, 81 % yield) of the resulting enol ether led to the targeted aldehyde **139**.

Following a previously developed strategy towards epothilone analogs (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, *123*, 9313–9323), aldehyde **139** (Figure 11) was

15   subjected to a Nozaki-Hiyama-Kishi coupling (Takai, K.; et al. *Tetrahedron Lett.* **1983**, *24*, 5281–5284; Jin, H.; et al. *J. Am. Chem. Soc.* **1986**, *108*, 5644–5646.) reaction with vinyl iodides **20a** (Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, *123*, 9313–9323) and **20b** (Nicolaou, K. C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432) followed by TBAF treatment to afford the corresponding secondary alcohols **141** and **143** as mixtures (ca

20   1:1) of the two epimers (at C-15) (42–45 % combined yield, unoptimized). These mixtures were then cyclized under Yamaguchi conditions, viz. 2,4,6-trichlorobenzoyl chloride, Et$_3$N, DMAP, toluene, 0–75 °C (Inanaga, J.; et al. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989–1993; Mulzer, J.; et al. *Synthesis* **1992**, 215–228) to afford the desired (15S) 16-membered lactones **142** (33 % yield) and **144** (32 % yield) together with their

25   (15R)-epimers (ca 1:1 ratio, chromatographically separated, silica gel. Based on previous experience, (Nicolaou, K. C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432) it was assumed that the desired (15S) macrolactones (**142** and **144**) eluted after their less polar (15R)- epimers, an assumption verified by their biological activities. Finally the TBS groups were removed from **142** and **144** by the action of TFA, leading to epothilones **106**

30   (48 % yield) and **104** (71 % yield) (unoptimized yields) as shown in Figure 11.

The biological activities of the synthesized epothilones were evaluated through cell growth inhibition assays (cytotoxicity assays). Cytotoxicity was first evaluated in a set of ovarian carcinoma cell lines, including a parental cell line (IA9) and three

35   drug-resistant cell lines, namely the paclitaxel-resistant cell lines IA9/PTX10 and

IA9/PTX22 (Giannakakou, P.; et al. *J. Biol. Chem.* **1997**, *272*, 17118–17125.) and the
epothilone-resistant cell line 1A9/A8 (Giannakakou, P.; et al. *Proc. Natl. Acad. Sci.* **2000**,
97, 2904–2909.). These resistant cell lines harbor distinct acquired β-tubulin mutations
which affect drug-tubulin interaction and result in impaired taxane and epothilone-driven

5 tubulin polymerization. The results of these biological investigations are summarized in
Figure 12. Further cytotoxicity studies were carried out using a set of human epidermoid
cancer cell lines, including a parent cell line (KB-31), and a paclitaxel-resistant (due to
Pgp overexpression) cell line (KB-8511). The results of these studies are summarized in
Figure 13.

10

There is a general agreement in the relative potency of the substituted epothilone
B analogs against the 1A9 human ovarian and the KB-31 human epidermoid cancer
cells. Collectively, the results of these cytotoxicity assays revealed interesting
information in terms of structure-activity relationships within the epothilone family. First,

15 compounds **104** and **106** in which the C_{12}-C_{13} epoxide moiety is replaced by a
cyclopropane ring are the two most potent compounds among all the epothilone B
analogs presented here. This result reaffirms that the C_{12}-C_{13} epoxide moiety is not
necessary for biological activity as previously noted (Nicolaou, K. C.; et al. *J. Am. Chem.
Soc.* **2001**, *123*, 9313–9323; Nicolaou, K. C.; et al. *ChemBioChem.* **2001**, *2*, 69–75;

20 Johnson, J. A.; et al. *Org. Lett.* **2000**, *2*, 1537–1540.). Compound **104** is 6-fold more
active than the parent epothilone B (**2**) against the 1A9 human ovarian carcinoma cells
(Figure 12) further confirming that the replacement of the methyl group on the thiazole
side-chain with a thiomethyl group leads to increased activity. This result is in agreement
with previous data on a similar substitution in epothilone B without replacement of the

25 C_{12}-C_{13} epoxide (i.e. compound **3**) (Nicolaou, K. C.; et al. *Tetrahedron* **2002**, *58*,
6413–6432). The latter compound (**3**) was about 2-fold more active than the parent
epothilone B, while compound **104** is 6-fold more potent than epothilone B. This result
makes compound **104**, the most active epothilone B analog against the 1A9 cell line
synthesized to date and suggests that replacement of the epoxide by a cyclopropane

30 moiety together with the replacement of the methyl substituent on the thiazole moiety
with a thiomethyl group act synergistically, leading to the observed enhancement of
biological activity. Interestingly, substitution of the methyl group of the thiazole ring with
larger moieties (compounds **107–10**) (The IC_{50} value for compound **107** was found to be
2.5 nM against the 1A9 cell line.) led to diminished biological activity as compared to

35 epothilone B (Figures 12 and 13).

Among the epothilone B analogs with substituted pyridine side-chains at the 5-position of the pyridine ring (compounds **111–113** and **115**), the thiomethyl analog (compound **113**) is the most potent followed by the bromo-substituted derivative (compound **111**) followed by the chloro-substituted system (compound **112**). When the

5   thiomethyl group is relocated from the 5-position of the pyridine ring (compound **113**) to the 6-position (compound **114**) loss of activity occurs as the IC_{50} value drops from 0.4 nM (compound **113**) to 3.3 nM (compound **114**) (Figure 12). Furthermore, replacement of the thiomethyl group at the 5-position of the pyridine ring (compound **113**) with a trifluoromethyl group (compound **115**) results in loss of activity by 10-fold. Finally, the

10   least active of the synthesized epothilone B analogs is compound **116** where a pyrimidine side-chain with a thiomethyl substitution has replaced the thiazole side-chain of the parent compound.

Varying degrees of cross-resistance are obtained with the substituted epothilone

15   B analogs against the paclitaxel- and epothilone-resistant human ovarian carcinoma sub-lines (Figure 12) ranging from 3- to 41-fold. These results suggest that the location of the tubulin mutations in these lines affects differentially the binding of each of the analogs to tubulin. Moreover, and in agreement with the original observations with the naturally occurring epothilones A and B, none of the epothilone B analogs tested herein

20   appears to be a good substrate for the drug-efflux pump P-glycoprotein (Pgp). This is evident by the lack of cross-resistance of each of these analogs to the Pgp-expressing cell line KB-8511 (Figure 13). In contrast, it has been previously shown that paclitaxel, a known Pgp substrate, was 214-fold less active against KB-8511 cells as compared to its action against their parental counterpart, non-Pgp-expressing KB-31 cells (Nicolaou, K.

25   C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432).

Experimental

General

30   All reactions were carried out under an argon atmosphere with dry solvents under anhydrous conditions, unless otherwise noted. Anhydrous solvents were obtained by passing them through commercially available activated alumina columns. All reagents were purchased at highest commercial quality and used without further purification. Reactions were generally monitored by thin-layer chromatography carried out on 0.25

35   mm E. Merck silica gel plates (60F-254). E. Merck silica gel (60, particle size 0.040-0.063

mm) was used for flash column chromatography. Preparative thin-layer chromatography (PTLC) separations were carried out on 0.25, 0.50 or 1 mm E. Merck silica gel plates (60F-254). Melting points (mp) are uncorrected and were recorded on a Thomas-Hoover Unimelt capillary melting point apparatus. Optical rotations were recorded on a

5   Perkin-Elmer 241 polarimeter. NMR spectra were recorded on Bruker DRX-600, DRX-500, AMX-400 or AC-250 instruments and calibrated using residual undeuterated solvents as an internal reference. All labeling of carbon atoms, *e.g.* C15, refers to epothilone A (**1**) numbering (see Figure 1). IR spectra were recorded on a Perkin-Elmer 1600 series FT-IR spectrometer. High resolution mass spectra were recorded on a

10   PerSeptive Biosystems Voyager™ IonSpec mass spectrometer (MALDI-FTMS) or on an API 100 Perkin-Elmer mass spectrometer (ESI).

Synthesis of epothilone 3

Stille coupling of vinyl iodide 15 with stannane 16.

15   A solution of $Pd_2(dba)_3(CHCl_3$ (3.9 mg, 3.8 µmol), $AsPh_3$ (4.6 mg, 15 µmol), and CuI (7.2 mg, 38 µmol) in DMF (degassed, 0.5 mL) was added at 25 °C to a solution of iodide **15** (10 mg, 19 µmol)(Nicolaou, K. C., et al., *Chem. Eur. J.* **2000**, *6*, 2783-2800) and stannane **16** (11 mg, 38 µmol) (Nicolaou, K. C., et al., *Bioorg. Med. Chem.* **1999**, *7*, 665-697) in DMF (degassed, 0.5 mL), and the resulting solution was stirred for 2 hours.

20   Water (10 mL) was added, and the mixture was extracted with EtOAc (3 (10 mL). The combined organic phase was washed with water (30 mL), brine (30 mL), and dried (Na_2SO_4). After evaporation of the volatiles, the residue was purified by flash column chromatography (sillica, hexanes:EtOAc 2:1 (1:1) to yield epothilone **3** as a white solid (7.2 mg, 72%); TLC R_f = 0.29 (silica, hexanes:EtOAc 1:1); $[\alpha]_D 22$ -53 (*c* 0.51, CH_2Cl_2); IR

25   (film) v_{max} 3472 (br), 2967, 2920, 1731, 1684, 1461, 1420, 1378, 1249, 1143, 1032, 973, 879, 732, 667 cm^{-1}; MALDI-FTMS *m/z* 562.2267 (MNa^+), calcd for $C_{27}H_{41}NO_6S_2Na$ 562.2267.

Construction of aldehyde 32

30   **Alcohol 23.** To a solution of cyclopropyl alcohol **22** (4.08 g, 24 mmol) (Charette, A. B.; et al. *J. Am. Chem. Soc.* **1998**, *120*, 11943-11952) in DMF (40 mL) was added sodium hydride (1.45 g, 36 mmol, 60% in mineral oil) portionwise with stirring at 0 °C. After stirring for 0.5 h at 25 °C, the mixture was cooled to 0 °C, benzyl bromide (4.3 mL, 36 mmol) was added over 2 min, and stirring was continued for 12 h at 25 °C The reaction

35   was quenched with NH_4Cl (sat., 50 mL), the mixture was extracted with EtOAc (3 (50

mL) and the combined extract was washed with brine (2 (100 mL), dried (Na_2SO_4) and evaporated. The residue was dissolved in CH_2Cl_2:MeOH 4:1 (60 mL), and the solution was ozonized (100 L/h, *ca.* 5 g O_3/h) at −78 °C for 21 min. (***NOTE:*** *Longer reaction times must be avoided to prevent oxidation of the benzyl ether to the corresponding benzoate.*)

5 Excess ozone was removed by flushing with N_2 for 1 min, and then $NaBH_4$ (2.75 g, 73 mmol) was added in small portions (***CAUTION!*** *Exothermic!*) followed by methanol (20 mL). The mixture was warmed to 25 °C over 1 hour, and the reaction was quenched by the addition of NH_4Cl (sat., 20 mL). The mixture was extracted with CH_2Cl_2 (2 (50 mL), and the combined extract was washed with brine (100 mL), dried (Na_2SO_4) and

10 evaporated. The residue was purified by flash chromatography (silica, hexanes:EtOAc 5:2) to yield **23** as a yellow oil (5.07 g, 89%). TLC R_f = 0.20 (silica, hexanes:EtOAc 3:1); $[\alpha]_D22$ −7.5 (*c* 1.76, $CHCl_3$); IR (film) v_{max} 3390 (br), 2933, 2859, 1452, 1070, 739, 698 cm^{-1}; MALDI-FTMS *m/z* 257.1519 (MNa^+), calcd for $C_{15}H_{22}O_2Na$ 257.1512.

15 **Iodide 24.** To a solution of cyclopropyl alcohol **23** (10.08 g, 43.0 mmol) in dry CH_2Cl_2 (100 mL) at 0 °C was added methanesulfonyl chloride (4.2 mL, 54 mmol) followed by triethylamine (9.0 mL, 65 mmol) dropwise. A white precipitate started to form immediately. The mixture was stirred at 25 °C for 1 hour, then NH_4Cl (sat., 50 mL) and water (50 mL) were added and the phases were separated. The aqueous phase was

20 extracted with EtOAc (100 mL), and the combined organic phase was washed with brine, dried (Na_2SO_4) and evaporated. The residue was dissolved in dry acetone (200 mL), and sodium iodide (19.3 g, 129 mmol) was added. The initially almost clear solution was refluxed for 40 min, during which time a white precipitate formed. Water (100 mL) was added and the mixture was extracted with ether (500 + 250 mL). The combined extract

25 was dried and evaporated, and the residue was purified by flash chromatography (silica, hexanes:EtOAc 5:1) to yield **24** as a colorless oil (14.16 g, 95%). TLC R_f = 0.66 (silica, hexanes:EtOAc 5:1); $[\alpha]_D22$ −16 (*c* 2.05, $CHCl_3$); IR (film) v_{max} 2916, 2848, 1453, 1217, 1098, 1073, 735, 697 cm^{-1}; ESI-MS *m/z* 367 (MNa^+), calcd for $C_{15}H_{21}IONa$ 367.

30 **Hydrazone 26.** A solution of LDA was prepared by adding *n*-BuLi (13.1 mL, 21.0 mmol, 1.6 M in hexanes) to diisopropylamine (2.94 mL, 21.0 mmol) in THF (10 mL) at −78 °C, then warming the solution to 0 °C, and stirring for 10 min. To this LDA solution was added propionaldehyde SAMP hydrazone **25** (3.32 g, 19.5 mmol) (Nicolaou, K. C., et al., *J. Am. Chem. Soc.* **1997**, *119*, 7974-7991; Enders, D. *Ayrmmetric Synth.* **1984**, *3*,

35 275-339; and Enders, D., et al., *Synthesis* **1996**, 1403-1418), and the mixture was stirred

for 6 h at 0 °C, during which time a white precipitate formed. The mixture was cooled to
−98 °C (MeOH/N$_2$(l) bath) and a solution of iodide **24** (5.16 g, 15.0 mmol) in THF (20 mL)
was added over 0.5 hour. The reaction mixture was then allowed to warm to −10 °C over
14 hours,' and then the reaction was quenched with NH$_4$Cl (sat., 10 mL). The mixture was
5   extracted with EtOAc (100 mL + 2 (50 mL), the combined extract was dried (Na$_2$SO$_4$)
and evaporated, and the residue was purified by flash chromatography (silica,
hexanes:EtOAc 6:1 (4:1) to yield hydrazone **26** as a yellow oil (4.88 g, 84%). TLC R_f =
0.38 (silica, hexanes:EtOAc 5:1); [α]$_D$22 −61 (c 1.45, CHCl$_3$); IR (film) V_{max} 2926, 1454,
1097, 736, 697 cm^{-1}; MALDI-FTMS m/z 387.3008 (MH$^+$), calcd for C$_{24}$H$_{39}$N$_2$O$_2$ 387.3006.
10

Aldehyde 17. A solution of hydrazone **26** (3.82 g, 9.9 mmol) in iodomethane (10 mL)
was heated at 60 °C (reflux condenser) for 3 hours, and was then cooled to 25 °C.
Excess iodomethane was evaporated and traces removed under oil pump vacuum. The
residual yellow syrup was vigorously stirred with 3 N HCl (190 mL) and pentane (190 mL)
15   for 3 h at 25 °C, the phases were separated, and the aqueous phase was extracted with
pentane (100 mL). The combined organic phase was dried (Na$_2$SO$_4$, NaHCO$_3$) and
evaporated to yield aldehyde **17** as a yellow oil (2.38 g, 88%). [α]$_D$22 +2 (c 1.3, CHCl$_3$);
IR (film) V_{max} 2931, 2856, 1724, 1454, 1095, 1074, 736, 698 cm^{-1}; MALDI-FTMS m/z
297.1830 (MNa$^+$), calcd for C$_{18}$H$_{26}$O$_2$Na 297.1825.
20

Due to the configurational lability at C8 (epothilone numbering), the aldehyde
should be used immediately in the next step. The dr at C8 was estimated as follows: A
sample of **17** was treated with excess NaBH$_4$ in methanol for 10 min. The reaction was
quenched with NH$_4$Cl (sat.), the mixture was extracted with EtOAc, and the extract was
25   dried (Na$_2$SO$_4$) and evaporated. The residue was treated with (R)-(−)-MTPACl (2-3
equiv.), excess triethylamine and 4-DMAP in CH$_2$Cl$_2$ for 3 hours. Purification by
preparative TLC yielded a sample of the (S)-MTPA ester, which by ^{1}H NMR analysis
showed a dr = 97:3, with the correct absolute stereochemistry at C8 as the major isomer
(Tsuda, M., et al., J. Org. Chem. **2000**, 65, 1349-1352). Analogous results were obtained
30   by using (S)-(+)-MTPACl.

Aldol product 27. A solution of LDA was prepared by adding n-BuLi (7.5 mL, 12 mmol,
1.6 M in hexanes) to diisopropylamine (1.68 mL, 12 mmol) in THF (12 mL) at −78 °C,
then warming the solution briefly to 0 °C, and finally cooling back to −78 °C. A solution of
35   ketone **19** (4.63 g, 11.5 mmol) (Nicolaou, K. C., et al., J. Am. Chem. Soc. **1997**, 119,

7974-7991) in THF (12 mL) was added dropwise over 2 min, and the mixture was stirred for 1 h at -78 °C and then for 0.5 h at -40 °C. It was again cooled to -78 °C, and a solution of aldehyde **17** (1.37 g, 5.0 mmol) in THF (25 mL), pre-cooled to -78 °C, was added via cannula over 1 min, taking care to ensure minimal warming during transfer. The mixture was stirred for 5 min, and the reaction was then quenched by rapid injection of a solution of AcOH (1.4 mL) in THF (4.2 mL). After 5 min at -78 °C, the mixture was warmed to 25 °C and partitioned between NH_4Cl (sat., 50 mL) and ether (50 mL). The aqueous phase was extracted with ether (2 (50 mL), the combined extract was dried (Na_2SO_4) and evaporated, and the residue was purified by flash chromatography (silica, hexanes:ether 20:1 (6:1) to yield recovered ketone **19** (1.71 g, 4.25 mmol) followed by the aldol product **27** in diastereomerically pure form (2.73 g, 81%). TLC R_f = 0.34 (silica, hexanes:EtOAc 5:1); $[\alpha]_D22$ -40 (c 1.0, $CHCl_3$); IR (film) v_{max} 3502 (br), 2954, 2928, 2856, 1681, 1472, 1255, 1098, 836, 776 cm^{-1}; MALDI-FTMS m/z 699.4796 (MNa$^+$), calcd for $C_{39}H_{72}O_5Si_2Na$ 699.4816.

Alcohol 28. A solution of aldol product **27** (2.71 g, 4.0 mmol) and 2,6-lutidine (1.40 mL, 12 mmol) in CH_2Cl_2 (25 mL) was cooled to -20 °C and then TBSOTf (1.84 mL, 8.0 mmol) was added dropwise. The mixture was stirred for 1 h at -20 °C and the reaction was then quenched by the addition of NH_4Cl (sat., 25 mL). The mixture was warmed to 25 °C, the phases were separated and the aqueous phase was extracted with CH_2Cl_2 (25 mL) and ether (25 mL). The combined organic phase was dried (Na_2SO_4) and evaporated, and the residue was filtered through a plug of silica eluting with hexane:ether 10:1. The filtrate was evaporated and the resulting crude silyl ether (3.14 g, 4.0 mmol, 99%) was dissolved in THF (40 mL). To this was added a cold (0 °C) solution of HF•pyridine complex (6.4 mL) and pyridine (18 mL) in THF (32 mL) at 0 °C (this solution was prepared by slowly adding the HF•pyridine complex to a solution of pyridine in THF at 0 °C; *CAUTION! HF•pyridine is highly corrosive. The addition of HF•pyridine to the pyridine-THF solution is highly exothermic, and must be done with stirring and cooling in ice bath to prevent splashing*), and the resulting solution was stirred at 25 °C for 4 hours. The mixture was diluted with EtOAc (100 mL), placed in an ice bath, and quenched by the careful addition of $NaHCO_3$ (sat., 100 mL) and as much solid $NaHCO_3$ as needed to ensure complete neutralization (*CAUTION! Foaming!*). The mixture was extracted with EtOAc (3 (100 mL), and the combined extract was dried (Na$_2$SO$_4$) and evaporated, and the residue was purified by flash chromatography (silica, hexanes:EtOAc 5:1) to yield **28** as a colorless oil (2.40 g, 89%). TLC R_f = 0.39 (silica, hexanes:EtOAc 5:1); $[\alpha]_D22$ -26 (c 1.1, $CHCl_3$); IR (film) v_{max}

3458 (br), 2929, 2856, 1693, 1472, 1462, 1255, 1093, 986, 836, 775 cm^{-1}; MALDI-FTMS m/z 699.4807 (MNa$^+$), calcd for $C_{39}H_{72}O_5Si_2Na$ 699.4816.

Ester 29: The alcohol **28** (2.40 g, 3.5 mmol), Dess-Martin periodinane (3.75 g, 8.8 mmol), NaHCO$_3$ (0.74 g, 8.8 mmol) and water (76 µL, 4.2 mmol) were mixed in CH$_2$Cl$_2$ (80 mL), and the resulting suspension was stirred for 1 hour. The mixture was diluted with ether (200 mL), water (100 mL) and NaHCO$_3$ (sat., 100 mL), and was then filtered. The phases were separated and the aqueous phase was extracted with ether (2 (100 mL). The combined extract was dried (Na$_2$SO$_4$) and evaporated, and the residue was filtered through a plug of silica eluting with hexanes:EtOAc 6:1. The filtrate was evaporated and the resulting crude aldehyde (2.15 g, 3.2 mmol, 90%) was dissolved in a mixture of THF (80 mL), *t*-BuOH (145 mL) and 2-methyl-2-butene (25 mL). To this solution was added a solution of NaH$_2$PO$_4$ (0.95 g, 6.7 mmol) and NaClO$_2$ (1.14 g, 10 mmol) in water (31 mL), and the resulting mixture was stirred vigorously for 1 hour. The volatiles were removed by evaporation, and the residue was partitioned between EtOAc (100 mL) and brine (100 mL). The phases were separated and the aqueous phase was extracted with EtOAc (3 (100 mL). The combined extract was dried (Na$_2$SO$_4$) and evaporated, and the residue was dissolved in DMF (5 mL) and evaporated again to remove traces of *t*-BuOH. The so obtained crude acid (2.4 g, *ca.* 3.2 mmol >100%,) was again dissolved in DMF (10 mL), to which 2-(trimethylsilyl)ethanol (1.83 mL, 12.7 mmol), EDC (0.92 g, 4.8 mmol), and 4-DMAP (40 mg, 0.33 mmol) were added. The resulting suspension was stirred for 14 hours, after which time a clear solution was obtained. Water (10 mL) was added and the mixture was extracted with ether (3 (50 mL). The combined extract was washed with water-brine mixture (100 + 100 mL), dried (Na$_2$SO$_4$) and evaporated. The residue was purified by flash chromatography (silica, hexanes:EtOAc 10:1) to yield ester **29** as a viscous, pale yellow oil (2.08 g, 74%). TLC R_f = 0.57 (silica, hexanes:EtOAc 10:1); [α]$_D$22 –33 (c 1.2, CHCl$_3$); IR (film) v_{max} 2954, 2930, 2856, 1735, 1695, 1472, 1385, 1252, 1090, 988, 836, 776 cm^{-1}; MALDI-FTMS *m/z* 813.5315 (MNa$^+$), calcd for $C_{44}H_{82}O_6Si_3Na$ 813.5311.

Aldehyde 30. To a solution of benzyl ether **29** (2.08 g, 2.63 mmol) in EtOH:EtOAc 1:1 (50 mL) was added 20% Pd(OH)$_2$ on carbon (2.1 g, 60% moisture), and the mixture was hydrogenated for 1 hour. It was then filtered through celite to remove the catalyst, the filtrate was evaporated, and the residue was co-evaporated with benzene to remove traces of EtOH. The resulting crude alcohol (1.89 g, *ca.* 2.6 mmol, >100%) was dissolved

in CH_2Cl_2 (60 mL), Dess-Martin periodinane (2.76 g, 6.5 mmol), $NaHCO_3$ (0.55 g, 6.5 mmol) and water (56 µL, 3.1 mmol) were added, and the resulting suspension was stirred for 1 hour. The mixture was diluted with ether (150 mL), water (75 mL) and $NaHCO_3$ (sat., 75 mL), and was then filtered. The phases were separated and the aqueous phase

5   was extracted with ether (2 (75 mL). The combined extract was dried (Na_2SO_4) and evaporated, and the residue was purified by flash chromatography (silica, hexanes:EtOAc 15:1) to yield aldehyde **30** as a viscous oil (1.55 g, 84%). TLC R_f = 0.24 (silica, hexanes:EtOAc 15:1); $[\alpha]_D 22$ –47 (c 1.3, $CHCl_3$); IR (film) v_{max} 2954, 2856, 1734, 1703, 1251, 1173, 1084, 988, 837, 776 cm^{-1}; MALDI-FTMS m/z 721.4671 (MNa$^+$), calcd

10   for $C_{37}H_{74}O_6Si_3Na$ 721.4685.

Enol ether 31. To a suspension of $MeOCH_2PPh_3Cl$ (3.09 g, 9.0 mmol) in THF (20 mL) at 0 °C was added NaHMDS (8.5 mL, 8.5 mmol, 1 M in THF) dropwise. A red color developed. The mixture was stirred at 0 °C for 0.5 h and it was then cooled to –40 °C. A

15   solution of aldehyde **30** (2.12 g, 3.0 mmol) in THF (7 mL) was added, and the mixture was allowed to warm to –10 °C over 2 hours. The reaction was quenched with NH_4Cl (sat., 15 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (2 (75 mL). The combined extract was dried (Na_2SO_4) and evaporated, and the residue was purified by flash chromatography (silica, hexanes:EtOAc 30:1) to yield enol

20   ether **31** as a colorless, viscous oil (1.85 g, 84%, olefin cis:trans ca. 1:1 by ^{1}H NMR). TLC R_f = 0.23 (silica, hexanes:EtOAc 30:1); $[\alpha]_D 22$ –36 (c 1.2, $CHCl_3$); IR (film) v_{max} 2954, 2930, 2856, 1735, 1695, 1251, 1171, 1105, 988, 836, 776 cm^{-1}; MALDI-FTMS m/z 749.4996 (MNa$^+$), calcd for $C_{39}H_{78}O_6Si_3Na$ 749.4998.

25   **Aldehyde 32.** To a solution of enol ether **31** (847 mg, 1.16 mmol) in dioxane:water 9:1 (12 mL) was added pyridinium para-toluenesulfonate (2.34 g, 9.31 mmol) and the mixture was stirred at 70 °C until TLC indicated the completion of the reaction (6-10 h). The reaction was then quenched with $NaHCO_3$ (sat., 15 mL), and the mixture was extracted with EtOAc (3 (50 mL). The combined extract was dried (Na_2SO_4) and evaporated, and

30   the residue was purified by flash chromatography (silica, hexanes:EtOAc 15:1) to yield **32** as a colorless, viscous oil (681 mg, 82%). TLC R_f = 0.29 (silica, hexanes:EtOAc 15:1); $[\alpha]_D 22$ –34 (c 1.0, $CHCl_3$); IR (film) v_{max} 2954, 2856, 1731, 1695, 1251, 1086, 988, 836, 776 cm^{-1}; MALDI-FTMS m/z 735.4823 (MNa$^+$), calcd for $C_{38}H_{76}O_6Si_3Na$ 735.4842.

35

Construction of vinyl iodides 20c–g

2-Brom -5-[(trityloxy)methyl]pyridine 34. Trityl chloride (3.90 g, 14 mmol), 4-DMAP (2.08 g, 17 mmol) and 2-bromo-5-hydroxymethylpyridine **33** (1.88 g, 10 mmol) (Ellingboe, J. W., et al., *J. Med. Chem.* **1994**, *37*, 542-550) were dissolved in DMF (15 mL) and the solution was stirred at 80 °C for 48 hours. A white precipitate formed during this time. After cooling, the mixture was diluted with $NaHCO_3$ (sat., 25 mL) and extracted with EtOAc (3 (50 mL). The combined extract was washed with brine, with a few drops of NaOH (1 M) added (2 (100 mL). After drying and evaporation, the solid residue was purified by flash chromatography (silica, hexanes:EtOAc 15:1) to yield **34** as a white solid (4.46 g, 100%). TLC R_f = 0.30 (silica, hexanes:EtOAc 15:1); IR (film) V_{max} 3057, 1448, 1086, 764, 700, 632 cm^{-1}; MALDI-FTMS m/z 430.0792 (MH$^+$), calcd for $C_{25}H_{21}BrNO$ 430.0801.

Sonogashira coupling of aryl bromdes (34, 37, 38, and 39) with propyne (general procedure). To a briefly deoxygenated (Ar bubbling) solution of the aryl bromide **34, 37, 38,** or **39** (3.5 mmol) in DMF (3 mL) and diisopropyl amine (2.5 mL) were added $Pd(PPh_3)_2Cl_2$ (25 mg, 36 µmol) and CuI (13 mg, 70 µmol) under Ar(g), and then the inert atmosphere was replaced by propyne (1 atm, balloon). The mixture was stirred at 25 °C for 3 hours. During this time, a precipitate formed, and the reaction mixture turned dark brown. Water (15 mL) was added, the mixture was extracted with EtOAc, and the combined extract was dried (Na_2SO_4) and evaporated. The pure 1-arylpropyne was obtained by flash chromatography (silica, hexane:EtOAc mixtures).

Propynylpyridine 35. Brown foam (96%); TLC R_f = 0.23 (silica, hexanes:EtOAc 5:1); IR (film) V_{max} 3057, 2229, 1594, 1560, 1478, 1448, 1075, 702 cm^{-1}; MALDI-FTMS m/z 390.1851 (MH$^+$), calcd for $C_{28}H_{24}NO$ 390.1852.

Pyridine 36. A solution of trityl ether **35** (1.38 g, 3.54 mmol) in $CHCl_3$ (15 mL) was cooled to 0 °C and then saturated with HCl (g). After 1 h at 0 °C, the reaction was quenched by the addition of $NaHCO_3$ (sat., 50 mL), and the phases were separated. The aqueous phase was extracted with CH_2Cl_2 (50 mL) and the combined organic phase was dried (Na_2SO_4) and evaporated. Flash chromatography (silica, hexanes:EtOAc 1:2 + 5% MeOH) afforded **5-hydroxymethyl-2-pr p-1-ynylpyridin** as a yellow, viscous oil (0.36 g, 69%). TLC R_f = 0.29 (silica, hexanes:EtOAc 1:2 + 5% MeOH); IR (film) V_{max} 3262, 2916, 2230, 1596, 1561, 1023, 838 cm^{-1}; MALDI-FTMS m/z 148.0754 (MH$^+$), calcd for

$C_9H_{10}NO$ 148.0757. To a solution of this alcohol (0.40 g, 2.7 mmol) in THF (10 mL) at 0 °C was added NaH (0.13 g, 3.3 mmol, 60% in oil). After stirring for 5 min, chloromethyl methyl ether (0.25 mL, 3.3 mmol) was added, and the mixture was stirred at 0 °C for 1 hour. The reaction was then quenched with NaCl (sat.), and a few drops of NaOH (1 M) were added. The mixture was extracted with EtOAc (3 (50 mL), the combined extract was dried (Na_2SO_4) and evaporated, and the residue was purified by flash chromatography (silica, hexanes:EtOAc 1:1) to yield **36** as a pale yellow oil (0.26 g, 50%). TLC R_f = 0.41 (silica, hexanes:EtOAc 1:1); IR (film) v_{max} 2947, 2230, 1595, 1560, 1478, 1149, 1104, 1047, 919, 830 cm^{-1}; MALDI-FTMS m/z 192.1014 (MH$^+$), calcd for $C_{11}H_{14}NO_2$ 192.1019.

Sonogashira coupling product from 37. The reaction was very slow, probably due to Pd coordination to the thioether moiety; therefore, 10 mol% $Pd(PPh_3)_2Cl_2$ and 20 mol% CuI were used. The product was obtained as a brown oil (42%). TLC R_f = 0.37 (silica, hexanes:EtOAc 15:1); IR (film) v_{max} 3110, 2914, 2240, 1493, 1417, 1278, 1037, 966, 735 cm^{-1}; MALDI-FTMS m/z 170.0092 (MH$^+$), calcd for $C_7H_8NS_2$ 170.0093.

Sonogashira coupling product from 38. Brown oil (97%); TLC R_f = 0.21 (silica, hexanes:EtOAc 5:1); IR (film) v_{max} 2908, 2226, 1567, 1531, 1461, 1431, 1361, 1108, 1008, 832 cm^{-1}; MALDI-FTMS m/z 164.0527 (MH$^+$), calcd for $C_9H_{10}NS$ 164.0528.

Sonogashira coupling product from 39. Yellow oil (70%); TLC R_f = 0.36 (silica, hexanes:EtOAc 20:1); IR (film) v_{max} 2924, 2231, 1566, 1554, 1431, 1156, 1140, 790 cm^{-1}; MALDI-FTMS m/z 164.0526 (MH$^+$), calcd for $C_9H_{10}NS$ 164.0528.

Hydrostannylation-iodination (general procedure). This is an adaption of the previously reported procedure (Betzer, J.-F., et al., *Tetrahedron Lett.* **1997**, *38*, 2279-2282). To a solution of hexabutylditin (10.1 mL, 20 mmol) in dry THF (40 mL) at –78 °C was added *n*-BuLi (12.9 mL, 20 mmol, 1.55 M in hexanes), and the resulting clear solution was stirred at –40 °C for 30 min. It was then transferred via cannula to a suspension of CuCN (0.90 g, 10 mmol) in THF (2 mL) at –78 °C. A clear yellow solution formed, and it was stirred for 5 min at –40 °C before being re-cooled to –78 °C. Then dry methanol (23 mL, 0.57 mol) was added to yield a red solution, which was stirred at –40 °C for 15 min, after which a solution of the arylpropyne (5.0 mmol) in THF (5 mL) was added. The orange-red solution was stirred at –10 °C overnight (some Cu and/or Cu^{2+} salts precipitate), then cooled to –20 °C, followed by the addition of methanol (10 mL).

After 15 min at −20 °C, water (10 mL) was added, and stirring was continued for another 15 min, while warming to 25 °C. The mixture was extracted with ether, and the organic phase was washed with brine, dried (Na_2SO_4) and evaporated. Flash chromatography (silica, hexanes:EtOAc mixtures) yielded the intermediate vinylstannane, which was

5 dissolved in CH_2Cl_2 (5 mL). A solution of iodine (1.05 equiv.) in CH_2Cl_2 (40 mL per g I_2) was then added dropwise to this solution at 0 °C. After the last few drops, the color of I_2 persisted, and the reaction was allowed to continue for another 5 min at 0 °C. Then the solvent was evaporated and the residue was dissolved in ether. KF (1 M solution in water, 3 equiv.) and $Na_2S_2O_3$ (sat., 10 mL per mmol substrate) were added, and the

10 mixture was stirred for 15 min at 25 °C during which time a white precipitate formed. The mixture was filtered through celite, and the organic phase was dried (Na_2SO_4) and evaporated. The residue was purified by flash chromatography (silica, hexanes:EtOAc mixtures) to yield the desired vinyl iodide.

15 **Vinyl iodide 20c.** White cloudy film (80%). TLC R_f = 0.25 (silica, hexanes:EtOAc 20:1); IR (film) v_{max} 3060, 2919, 1619, 1596, 1484, 1443, 1373, 1214, 1061, 985, 873, 761, 703, 632 cm^{-1}; MALDI-FTMS m/z 518.0990 (MH^+), calcd for $C_{28}H_{25}INO$ 518.0975.

Vinyl iodide 20d. Yellow oil (67%). TLC R_f = 0.51 (silica, hexanes:EtOAc 4:1); IR (film)
20 v_{max} 2924, 1716, 1619, 1596, 1481, 1372, 1211, 1149, 1102, 1045, 918, 873, 609, 517 cm^{-1}; MALDI-FTMS m/z 320.0142 (MH^+), calcd for $C_{11}H_{15}INO_2$ 320.0142.

Vinyl iodide 20e. The intermediate vinyl stannane is readily protodestannylated; therefore, flash chromatography of this intermediate must be performed using
25 hexanes:EtOAc:Et_3N 50:1:1 as eluent, and the so obtained vinylstannane contained other butyl tin compunds. Following the general procedure, the mixture was treated with enough I_2 that the brown color persisted at the end of the addition (ca. 2 equiv. of I_2). After flash chromatography (hexanes:EtOAc 50:1), vinyl iodide **20e** was obtained as a yellow oil (74%). TLC R_f = 0.41 (silica, hexanes:EtOAc 50:1); IR (film) v_{max} 3102, 2923,
30 1620, 1423, 1300, 1065, 1035, 964, 863, 723, 562 cm^{-1}; MALDI-FTMS m/z 297.9215 (MH^+), calcd for $C_7H_9INS_2$ 297.9216.

Vinyl iodide 20f. Yellow solid (80%). TLC R_f = 0.19 (silica, hexanes:EtOAc 40:1); IR (film) v_{max} 2919, 1619, 1567, 1467, 1431, 1373, 1108, 1067, 1014, 961, 867, 820, 521
35 cm^{-1}; MALDI-FTMS m/z 291.9655 (MH^+), calcd for $C_9H_{11}INS$ 291.9651.

Vinyl iodide 20g. Yellow oil (83%). TLC R_f = 0.28 (silica, hexanes:EtOAc 40:1); IR (film) v_{max} 2919, 1620, 1549, 1425, 1155, 1138, 1061, 991, 961, 861, 785, 732, 550 cm^{-1}; MALDI-FTMS m/z 291.9653 (MH$^+$), calcd for $C_9H_{11}INS$ 291.9651.

Synthesis of epothilone analogues 8–144.

Nozaki-Hiyama-Kishi coupling of aldehydes (34, 40) with vinyl stannanes (20a–g) (general procedure). To a briefly vacuum-degassed solution of aldehyde **32** (107 mg, 0.15 mmol), the requisite vinyl iodide **20** (0.45 mmol), and 4-*tert*-butylpyridine (665 µL, 4.5 mmol) in DMSO (3 mL) were added anhydrous $CrCl_2$ (184 mg, 1.5 mmol) and anhydrous $NiCl_2$ (4 mg, 0.03 mmol). The mixture was stirred at 25 °C for 3 hours, after which another portion of vinyl iodide (0.45 mmol) was added, and stirring was continued for a further 3 hours. This was repeated one more time, after which stirring was continued overnight. The reaction was then quenched with water (5 mL), pyridine (1 mL) was added to prevent Cr-product complexes from being extracted into the water phase, and the mixture was extracted with EtOAc (3 (25 mL). The combined extract was washed with brine (2 (100 mL), dried (Na_2SO_4) and evaporated. Flash chromatography (silica, hexanes:EtOAc mixtures) yielded the coupling product, in most cases inseparable from excess 4-*tert*-butylpyridin.

Product from 20a and 32. Yellow oil (85% as a *ca.* 1:1 mixture of C15 epimers). TLC R_f = 0.26 (silica, hexanes:EtOAc 4:1); $[\alpha]_D$22 –25 (*c* 0.36, CH_2Cl_2); IR (film) v_{max} 2943, 2860, 1731, 1696, 1467, 1384, 1290, 1249, 1173, 1079, 985, 832, 773 cm^{-1}; MALDI-FTMS m/z 860.5128 (MNa$^+$), calcd for $C_{44}H_{83}NO_6SSi_3Na$ 860.5141.

Product from 20b and 32. This coupling product was inseparable from 4-*tert*-butyl pyridine, and was subjected to the TBAF deprotection conditions (vide infra) as a crude mixture.

Product from 20d and 32. This coupling product was inseparable from 4-*tert*-butyl pyridine, and was subjected to the TBAF deprotection conditions (vide infra) as a crude mixuture.

Product from 20e and 32. Yellow glass (78%, *ca.* 1:1 mixture of C15 epimers). TLC R_f = 0.40 (silica, hexanes:EtOAc 5:1); $[\alpha]_D$22 –28 (*c* 2.0, $CHCl_3$); IR (film) v_{max} 3416 (br), 2929, 2856, 1732, 1694, 1472, 1251, 1037, 988, 836, 776 cm^{-1}; MALDI-FTMS m/z 906.5021

(MH⁺), calcd for $C_{45}H_{85}NO_6S_2Si_3Na$ 906.5018.

Product from 20f and 32. This coupling product was inseparable from 4-*tert*-butyl pyridine, and was subjected to the TBAF deprotection conditions (vide infra) as a crude mixture.

Product from 20g and 32. This coupling product was inseparable from 4-*tert*-butyl pyridine, and was subjected to the TBAF deprotection conditions (vide infra) as a crude mixture.

Product from 20c and 40. Yellow glass (87% for two steps from aldehyde **40** as a *ca.* 1:1 mixture of C15 epimers). TLC R_f = 0.15 (silica, hexanes:EtOAc 4:1); $[\alpha]_D22$ -23 (*c* 0.19, CH_2Cl_2); IR (film) v_{max} 2931, 2861, 1731, 1690, 1467, 1384, 1355, 1249, 1167, 1061, 985, 832, 773, 703 cm^{-1}; MALDI-FTMS *m/z* 1112.6634 (MNa⁺), calcd for $C_{65}H_{99}NO_7Si_3Na$ 1112.6621.

Product from 20e and 40. Colorless glass (59%, *ca.* 1:1 mixture of C15 epimers). TLC R_f = 0.27 (silica, hexanes:EtOAc 5:1); $[\alpha]_D22$ –28 (*c* 2.0, $CHCl_3$); IR (film) v_{max} 3396 (br), 2928, 2855, 1734, 1693, 1472, 1251, 1037, 988, 836, 775 cm^{-1}; MALDI-FTMS *m/z* 892.4861 (MNa⁺), calcd for $C_{44}H_{83}NO_6S_2Si_3Na$ 892.4862.

TBAF deprotection (general procedure). The product mixture from the Nozaki-Hiyama-Kishi coupling was dissolved in THF (1.5 mL), and TBAF (1 M in THF, 0.30 mL, 0.30 mmol) was added at 0 °C. After 1 h at 0 °C, another portion of TBAF (0.30 mL, 0.30 mmol) was added, and the mixture was stirred at 25 °C for 1 hour. The reaction was quenched with NH_4Cl (sat., 5 mL), and the mixture was extracted with EtOAc (4 (20 mL). The combined extract was dried (Na_2SO_4) and evaporated, and the residue was purified by flash chromatography (silica, hexanes:EtOAc mixtures) to yield the desired hydroxy acid as a *ca.* 1:1 mixture of C15 epimers (inseparable at this stage).

Hydroxy acid 41a. The reaction mixture from the deprotection was quickly filtered through a plug of silica gel, and this crude product (73% yield from aldehyde **32**) was subjected to the Yamaguchi macrolactonization (*vide infra*) without further purification.

Hydroxy acid 41b. Yellow solid (57%, *ca.* 1:1 mixture of C15 epimers). TLC R_f = 0.19 (silica, hexanes:EtOAc 2:1); $[\alpha]_D22$ –6 (*c* 1.0, $CHCl_3$); IR (film) v_{max} 3369 (br), 2930, 2857,

1783, 1694, 1471, 1251, 1085, 1084, 988, 836, 775 cm^{-1}; MALDI-FTMS m/z 768.5028 (MNa$^+$), calcd for $C_{42}H_{75}NO_6Si_2Na$ 768.5025.

Hydroxy·acid 41d. Yellow glass (49% for 2 steps from aldehyde **32** as a $ca.$ 1:1 mixture of C15 epimers). TLC R_f = 0.20 (silica, hexanes:EtOAc 1:1); [α]$_D$22 +1 (c 0.19, CH$_2$Cl$_2$); IR (film) v_{max} 2933, 2858, 1694, 1600, 1563, 1463, 1382, 1357, 1251, 1145, 1096, 1046, 989, 834, 772, 666 cm^{-1}; MALDI-FTMS m/z 806.5437 (MH$^+$), calcd for $C_{44}H_{80}NO_8Si_2$ 806.5417.

Hydroxy acid 41e. Yellow solid (79%, $ca.$ 1:1 mixture of C15 epimers). TLC R_f = 0.37 (silica, hexanes:EtOAc 2:1); [α]$_D$22 –23 (c 2.3, CHCl$_3$); IR (film) v_{max} 3356 (br), 2929, 2856, 1712, 1472, 1253, 1085, 1038, 988, 836, 776 cm^{-1}; MALDI-FTMS m/z 806.4282 (MNa$^+$), calcd for $C_{40}H_{73}NO_6S_2Si_2Na$ 806.4315.

Hydroxy acid 41f. Colorless glass (63%, $ca.$ 1:1 mixture of C15 epimers). TLC R_f = 0.21 (silica, hexanes:EtOAc 2:1); [α]$_D$22 –3 (c 0.44, CH$_2$Cl$_2$); IR (film) v_{max} 2933, 2858, 1693, 1467, 1253, 1086, 984, 833, 774 cm^{-1}; MALDI-FTMS m/z 800.4754 (MNa$^+$), calcd for $C_{42}H_{75}NO_6SSi_2Na$ 800.4746.

Hydroxy acid 41g. Yellow glass (46% for 2 steps from aldehyde **32** as a $ca.$ 1:1 mixture of C15 epimers). TLC R_f = 0.46 (silica, hexanes:EtOAc 2:1); [α]$_D$22 –11 (c 0.19, CH$_2$Cl$_2$); IR (film) v_{max} 2933, 2858, 1706, 1557, 1463, 1426, 1364, 1251, 1083, 989, 834, 772, 666 cm^{-1}; MALDI-FTMS m/z 800.4746 (MNa$^+$), calcd for $C_{42}H_{75}NO_6SSi_2Na$ 800.4746.

Hydroxy acid 42c. The reaction mixture from the deprotection was quickly filtered through a plug of silica gel, and this crude product (46% yield from aldehyde **40**) was subjected to the Yamaguchi macrolactonization (vide infra) without further purification.

Hydroxy acid 42e. Pale yellow glass (66%, $ca.$ 1:1 mixture of C15 epimers). TLC R_f = 0.39 (silica, hexanes:EtOAc 2:1); [α]$_D$22 –20 (c 1.0, CHCl$_3$); IR (film) v_{max} 3354 (br), 2928, 2856, 1713, 1471, 1253, 1087, 988, 836, 775 cm^{-1}; MALDI-FTMS m/z 792.4161 (MNa$^+$), calcd for $C_{39}H_{71}NO_6S_2Si_2Na$ 792.4153.

Yamaguchi macrolact nization (general procedure). To a solution of the hydroxy acid (95 µmol) in dry THF (8 ml) at 0 °C was added triethylamine (79 µl, 0.57 mmol) and 2,4,6-trichlorobenzoyl chloride (40 µl, 0.23 mmol). After stirring at 0 °C for 1 hour, the

resulting solution was added over 2 h to a solution of 4-DMAP (26 mg, 0.21 mmol) in toluene (20 mL) at 75 °C using a syringe pump. Stirring was continued at 75 °C for another 1 h after which the toluene was evaporated under reduced pressure. The residue was directly subjected to flash chromatography (silica, hexanes:EtOAc mixtures) to yield

5   the macrolactone and its (15R)-epimer, readily separable. In all cases the desired (15S)-epimer eluted *after* the less polar (15R)-epimer.

Macrolactone 43a. colorless glass (28% for two steps from the Nozaki-Hiyama-Kishi coupling product of aldehyde **32** and vinyl iodide **20a**.); TLC R_f = 0.21 (silica,

10   hexanes:EtOAc 20:1); $[\alpha]_D22$ –33 (c 0.56, CH_2Cl_2); IR (film) v_{max} 2932, 2855, 1739, 1689, 1465, 1383, 1252, 1181, 1153, 1099, 1066, 1017, 984, 869, 836, 776 cm^{-1}; MALDI-FTMS m/z 734.4639 (MH$^+$), calcd for $C_{40}H_{72}NO_5SSi_2$ 734.4664.

Macrolactone 43b. Colorless glass (28%); TLC R_f = 0.27 (silica, hexanes:EtOAc 10:1);

15   $[\alpha]_D22$ –28 (c 1.0, CHCl$_3$); IR (film) n_{max} 2929, 2856, 1740, 1695, 1472, 1384, 1253, 1100, 1020, 986, 836, 775 cm^{-1}; MALDI-FTMS m/z 728.5109 (MH$^+$), calcd for $C_{42}H_{74}NO_5Si_2$ 728.5106.

Macrolactone 43d. Yellow glass (35%); TLC R_f = 0.14 (silica, hexanes: EtOAc 6:1);

20   $[\alpha]_D22$ –28 (c 0.12, CH_2Cl_2); IR (film) v_{max} 2931, 2861, 1737, 1690, 1596, 1467, 1378, 1249, 1149, 1102, 1049, 985, 832, 773 cm^{-1}; MALDI-FTMS m/z 810.5116 (MNa$^+$), calcd for $C_{44}H_{77}NO_7Si_2Na$ 810.5130.

Macrolactone 43e. This product was isolated as a crude mixture which was directly

25   subjected to the global desilylation conditions (*vide infra*) without further purification.

Macrolactone 43f. Colorless glass (45%); TLC R_f = 0.20 (silica, hexanes:EtOAc 10:1); $[\alpha]_D22$ -0.30 (c 0.10, CH_2Cl_2); IR (film) v_{max} 2933, 285, 1737, 1668, 1463, 1382, 1357, 1251, 1102, 1015, 983, 871, 834, 772 cm^{-1}; MALDI-FTMS m/z 760.4799 (MH$^+$), calcd for

30   $C_{42}H_{74}NO_5SSi_2$ 760.4820.

Macrolactone 43g Yellow glass (37%); TLC R_f = 0.47 (silica, hexanes:EtOAc 10:1); $[\alpha]_D22$ –14 (c 0.31, CHCl$_3$); IR (film) v_{max} 2929, 2856, 1740, 1696, 1557, 1461, 1431, 1379, 1250, 1099, 107, 979, 836, 774 cm^{-1}; MALDI-FTMS m/z 760.4802 (MH$^+$), calcd for

35   $C_{42}H_{74}NO_5SSi_2$ 760.4820.

Macrolactone 44c. Colorless glass (33% for 2 steps from the Nozaki-Hiyama-Kishi coupling product of aldehyde **40** and vinyl iodide **20c**); TLC R_f = 0.46 (silica, hexanes:EtOAc 10:1); $[\alpha]_D22$ −17 (c 0.56, CH_2Cl_2); IR (film) ν_{max} 2931, 2861, 1743, 1696, 1467, 1378, 1249, 1161, 1073, 1020, 985, 873, 833, 773, 703, 579 cm^{-1}; MALDI-FTMS m/z 972.5969 (MH$^+$), calcd for $C_{60}H_{86}NO_6Si_2$ 972.5988.

Macrolactone 44e. Colorless glass (47%); TLC R_f = 0.31 (silica, hexanes:EtOAc 15:1); $[\alpha]_D22$ −19 (c 0.50, $CHCl_3$); IR (film) ν_{max} 2929, 2855, 1741, 1697, 1472, 1254, 1102, 1036, 986, 836, 775 cm^{-1}; MALDI-FTMS m/z 774.4056 (MNa$^+$), calcd for $C_{39}H_{69}NO_5S_2Si_2Na$ 774.4048.

Global desilylation (general procedure). The macrolactone was dissolved in 20% v/v TFA in CH_2Cl_2, and the solution was kept at 25 °C for 3 hours, after which the volatiles were evaporated without heating. The residue was dissolved in EtOAc, and the solution was washed with $NaHCO_3$ (sat.), dried (Na_2SO_4) and evaporated. Flash chromatography (silica, hexanes:EtOAc mixtures) afforded the pure epothilone.

Epothilone 6. Colorless glass (73%); TLC R_f = 0.25 (silica, hexanes:EtOAc 2:1); $[\alpha]_D22$ −34 (c 0.11, CH_2Cl_2); IR (film) ν_{max} 3472 (br), 2931, 1732, 1684, 1456, 1378, 1258, 1179, 1149, 1067, 1043, 1012, 973, 873, 732 cm^{-1}; MALDI-FTMS m/z 506.2931 (MH$^+$), calcd for $C_{28}H_{44}NO_5S$ 506.2935.

Epothilone 8. Colorless glass (48%); TLC R_f = 0.52 (silica, hexanes:EtOAc 1:1); $[\alpha]_D22$ −54 (c 0.30, $CHCl_3$); IR (film) ν_{max} 3445 (br), 2936, 1732, 1682, 1454, 1383, 1259, 756 cm^{-1}; MALDI-FTMS m/z 500.3369 (MH$^+$), calcd for $C_{30}H_{46}NO_5$ 500.3376.

Epothilone 10. The general procedure failed to cleave the MOM protecting group cleanly. Therefore, this group was first removed using bromotrimethylsilane as follows: To a solution of protected epothilone **43d** (11 mg, 14 μmol) in dry CH_2Cl_2 (0.4 mL) was added powdered 4Å MS (5 mg), and the resulting mixture was cooled to −30 °C. Bromotrimethylsilane (18.4 μL, 140 μmol) was added dropwise, and the mixture was stirred at −30 °C for 1 hour, after which the reaction was quenched with $NaHCO_3$ (sat.) and extracted five times with EtOAc. The combined extract was dried and evaporated,

and the residue subjected to the general desilylation procedure to yield **10** as a colorless glass (56%); TLC R_f = 0.42 (silica, hexanes:EtOAc 1:4); $[\alpha]_D22$ –52 (c 0.12, CH_2Cl_2); IR (film) V_{max} 3401 (br), 2931, 1731, 1684, 1596, 1561, 1461, 1378, 1331, 1290, 1255, 1173, 1149, 1044, 1008, 979, 879, 732 cm^{-1}; MALDI-FTMS m/z 516.3330 (MH⁺), calcd for $C_{30}H_{46}NO_6$ 516.3319.

Epothilone 12. Viscous oil (17% from **41e**); TLC R_f = 0.38 (silica, hexanes:EtOAc 2:1); $[\alpha]_D22$ –52 (c 0.50, $CHCl_3$); IR (film) V_{max} 3490 (br), 2933, 1732, 1686, 1255, 1038, 756 cm^{-1}; MALDI-FTMS m/z 538.2666 (MH⁺), calcd for $C_{28}H_{44}NO_5S_2$ 538.2655.

Epothilone 13. Colorless glass (68%); TLC R_f = 0.57 (silica, hexanes:EtOAc 1:1); $[\alpha]_D22$ –46 (c 0.34, CH_2Cl_2); IR (film) V_{max} 3484 (br), 2932, 1731, 1684, 1469, 1367, 1255, 1150, 1044, 1009, 973, 879, 826, 732 cm^{-1}; MALDI-FTMS m/z 554.2915 (MNa⁺), calcd for $C_{30}H_{45}NO_5SNa$ 554.2910.

Epothilone 14. Colorless glass (48%); TLC R_f = 0.42 (silica, hexanes:EtOAc 2:1); $[\alpha]_D22$ –38 (c 0.34, CH_2Cl_2); IR (film) V_{max} 3478 (br), 2930, 1732, 1682, 1556, 1434, 1378, 1257, 1149, 1137, 1067, 1044, 1012, 979, 785, 732 cm^{-1}; MALDI-FTMS m/z 532.3078 (MH⁺), calcd for $C_{30}H_{45}NO_5S$ 532.3091.

Epothilone 9. Colorless glass (54%); TLC R_f = 0.13 (silica, hexanes:EtOAc 1:2); $[\alpha]_D22$ -24 (c 0.14, CH_2Cl_2); IR (film) V_{max} 3379, 2920, 2857, 1725, 1688, 1600, 1459, 1370, 1255, 1151, 1047, 1010, 979, 880, 734 cm^{-1}; MALDI-FTMS m/z 524.3004 (MNa⁺), calcd for $C_{29}H_{43}NO_6Na$ 524.2982.

Epothilone 11. Colorless glass (68%); TLC R_f = 0.28 (silica, hexanes:EtOAc 2:1); $[\alpha]_D22$ –26 (c 0.30, $CHCl_3$); IR (film) V_{max} 3444 (br), 2925, 1731, 1693, 1454, 1258, 1037, 756 cm^{-1}; MALDI-FTMS m/z 546.2330 (MNa⁺), calcd for $C_{27}H_{41}NO_5S_2Na$ 546.2318.

Compound 104: R_f = 0.19 (silica gel, ethyl acetate/hexanes = 3/7); $[\alpha]_D^{20}$ –19.3 (c 0.14, CH_2Cl_2); IR (film): v_{max} 3484 (br), 2932, 1729, 1459, 1375, 1249, 1043, 982, 733 cm^{-1}; ¹H NMR (400 MHz, $CDCl_3$): δ = 6.97 (s, 1 H), 6.47 (s, 1 H), 5.25 (dd, J = 7.1, 5.7 Hz, 1 H), 4.04 (dd, J = 8.1, 3.0 Hz, 1 H), 3.91 (dd, J = 4.1, 4.1 Hz, 1 H), 3.23 (m, 1 H), 2.69 (s, 3 H), 2.52 (dd, J = 14.9, 8.4 Hz, 1 H), 2.46 (dd, J = 14.9, 2.6 Hz, 1 H), 2.11 (s, 3 H), 2.04 (dd, J = 14.5, 4.0 Hz, 1 H), 1.66–1.72 (m, 1 H), 1.44–1.62 (m, 4 H), 1.36 (s, 3 H),

1.22–1.35 (m, 2 H), 1.17 (d, J = 7.5 Hz, 3 H), 1.16 (s, 3 H), 1.04–1.15 (m, 1 H), 0.99 (d, J = 7.0 Hz, 3 H), 0.97 (s, 3 H), 0.48 (m, 1 H), 0.40 (dd, J = 8.8, 3.9 Hz, 1 H), –0.11 ppm (br t, J = 4.6 Hz, 1 H); ^{13}C NMR (100 MHz, $CDCl_3$): δ = 221.5, 171.1, 165.7, 152.9, 138.6, 120.1, 116.2, 82.0, 73.8, 73.2, 52.0, 42.9, 39.4, 36.5, 35.0, 33.2, 31.6, 24.6, 23.5, 22.54,

5   22.49, 21.1, 20.8, 19.4, 17.4, 16.8, 15.0, 13.2 ppm; MALDI-FTMS: m/z 538.2632 (MH$^+$), calcd for $C_{28}H_{44}NO_5S_2$ 538.2655.

Compound 106: R_f = 0.27 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -61 (c 0.12, CH_2Cl_2); MALDI-FTMS: m/z 500.3376 (MH$^+$), calcd for $C_{30}H_{46}NO_5$ 500.3370.

10

Compound 107: R_f = 0.37 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -44 (c 0.14, CH_2Cl_2); MALDI-FTMS: m/z 554.2604 (MH$^+$), calcd for $C_{28}H_{44}NO_6S_2$ 554.2604.

Compound 108: R_f = 0.31 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -32 (c 0.33,

15   CH_2Cl_2); MALDI-FTMS: m/z 608.2334 (MH$^+$), calcd for $C_{28}H_{41}F_3NO_6S_2$ 608.2322.

Compound 109: R_f = 0.38 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -43 (c 0.12, CH_2Cl_2); MALDI-FTMS: m/z 568.2777 (MH$^+$), calcd for $C_{29}H_{46}NO_6S_2$ 568.2761.

20   **Compound 110**: R_f = 0.27 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -28 (c 0.26, CH_2Cl_2); MALDI-FTMS: m/z 628.2376 (MNa$^+$), calcd for $C_{31}H_{43}NO_7S_2Na$ 628.2373.

Compound 111: R_f = 0.24 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -49 (c 0.45, CH_2Cl_2); MALDI-FTMS: m/z 566.2116 (MH$^+$), calcd for $C_{28}H_{41}BrNO_6$ 566.2112.

25

Compound 112: R_f = 0.36 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -27 (c 0.15, CH_2Cl_2); MALDI-FTMS: m/z 544.2419 (MNa$^+$), calcd for $C_{28}H_{40}ClNO_6Na$ 544.2436.

Compound 113: R_f = 0.28 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -49 (c 0.45,

30   CH_2Cl_2); MALDI-FTMS: m/z 534.2907 (MH$^+$), calcd for $C_{29}H_{44}NO_6S$ 534.2884.

Compound 114: R_f = 0.35 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -50 (c 0.62, CH_2Cl_2); MALDI-FTMS: m/z 556.2724 (MNa$^+$), calcd for $C_{29}H_{43}NO_6SNa$ 556.2703.

35   **Compound 17**: R_f = 0.37 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -34 (c 0.24,

CH_2Cl_2); MALDI-FTMS: m/z 556.2891 (MH$^+$), calcd for $C_{29}H_{41}F_3NO_6$ 556.2880.

Compound 116: R_f = 0.34 (silica gel, ethyl acetate/hexanes = 1/1); $[\alpha]_D20$ -33 (c 0.80, CH_2Cl_2); MALDI-FTMS: m/z 535.2820 (MH$^+$), calcd for $C_{28}H_{43}N_2O_6S$ 535.2836.

<u>Detailed Description of Figures</u>

Figure 1 illustrates the structures of selected natural and designed epothilones. Grey boxes indicate compounds synthesized in this study.

Figure 2 illustrates a chart showing the displacement of the fluorescent taxoid Flutax-2 (50 nM) from microtubule binding sites (50 nM) by competing ligands at 37 °C. The dots indicate acquired data points and the lines were generated so that they give the best fit value of the binding equilibrium constant of each competitor, assuming one-to-one binding to the same site. Ligands assayed are paclitaxel (Taxol$^®$) (dark blue), epothilone A (**1**) (red), epothilone B (**2**) (violet), compound **3** (yellow), compound **4** (light brown), and compound **8** (green). Representative curves for selected epothilone analogues (**3**, **4**, and **8**) are presented in this figure to exemplify how the binding affinities were measured for each compound in Table 3.

Figure 3 illustrates the synthesis of 2-(thiomethyl)thiazole epothilone B (**3**) via Stille coupling. *Reagents and conditions*: $Pd_2(dba)_3 \cdot CHCl_3$ (0.2 equiv), CuI (2.0 equiv), $AsPh_3$ (0.8 equiv), DMF, 25 °C, 80%. dba = dibenzylideneacetone.

Figure 4 illustrates the retrosynthetic analysis of *trans*-cyclopropyl epothilone B analogues (**1 - 6, 8, 10, 12–14**).

Figure 5 illustrates the construction of aldehyde **32**. *Reagents and conditions*: (a) See Nicolaou, K. C., et al. *ChemBioChem* **2001**, *2*, 69-75; Charette, A. B.; et al. *J. Am. Chem. Soc.* **1998**, *120*, 11943-11952; (b) NaH (1.5 equiv), BnBr (1.5 equiv), DMF, 0 → 25 °C, 12 h; (c) O_3, CH_2Cl_2:MeOH 4:1, –78 °C, 21 min; then $NaBH_4$ (3.0 equiv), –78 → 25 °C, 1 h, 89% for 2 steps; (d) MsCl (1.3 equiv), Et_3N (1.5 equiv), CH_2Cl_2, 25 °C , 1 h; (e) NaI (3.0 equiv), acetone, reflux, 40 min, 95% for 2 steps; (f) LDA (1.4 equiv), **25** (1.3 equiv), THF, 0 °C, 6 h; then **24**, –98 → –10 °C, 14 h, 84%; (g) MeI, 60 °C, 3 h; (h) 3 N HCl:pentane 1:1, 25 °C, 3 h, 88% for 2 steps; (i) LDA (2.4 equiv), **19** (2.3 equiv), THF, –78 °C, 1 h; then –40 °C, 0.5 h; then **17** at –78 °C, 5 min, 81%; (j) TBSOTf (2.0 equiv), 2,6-lutidine (3.0 equiv), CH_2Cl_2, –20 °C, 1 h; (k) HF•py, pyridine, THF, 25 °C, 4 h, 89% for 2 steps; (l) DMP (2.5 equiv), $NaHCO_3$ (2.5 equiv), H_2O, CH_2Cl_2, 25 °C, 1 h; (m) $NaClO_2$ (3.1 equiv), NaH_2PO_4 (2.1 equiv), 2-methyl-2-butene (74 equiv), *t*-BuOH, THF, H_2O, 25 °C, 1 h; (n) 2-(trimethylsilyl)ethanol (4.0 equiv), EDC (1.5 equiv), 4-DMAP (0.1 equiv),

DMF, 25 °C, 14 h, 74% for 3 steps; (o) 20% Pd(OH)$_2$/C, H$_2$ (1 atm), EtOH:EtOAc 1:1, 25 °C, 1 h; (p) DMP (2.5 equiv), NaHCO$_3$ (2.5 equiv), H$_2$O, CH$_2$Cl$_2$, 25 °C, 1 h, 84% for 2 steps; (q) MeOCH$_2$PPh$_3$Cl (3.0 equiv), NaHMDS (2.8 equiv), THF, −40 → −10 °C, 2 h, 84%; (r) PPTS (8.0 equiv), dioxane:H$_2$O 9:1, 70 °C, 6 h, 82%. 4-DMAP = 4-(dimethylamino)pyridine; DME = 1,2-dimethoxy-ethane; DMP = Dess-Martin periodinane; EDC = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HF•py = hydrogen fluoride-pyridine complex; NaHMDS = sodium hexamethyldisilazide; PPTS = pyridinium para-toluenesulfonate; TMSE = 2-trimethylsilylethyl.

Figure 6 illustrates the construction of vinyl iodides **20c–g**. *Reagents and conditions*: (a) TrCl (1.4 equiv), 4-DMAP (1.7 equiv), DMF, 80 °C, 48 h, 100%; (b) Pd(PPh$_3$)$_2$Cl$_2$ (0.01 equiv), CuI (0.02 equiv), HC≡CCH$_3$ (1 atm), DMF, *i*-Pr$_2$NEt, 25 °C, 3 h, **35**: 96%; (c) (i) *n*-BuLi (4.0 equiv), (*n*-Bu$_3$Sn)$_2$ (4.0 equiv), CuCN (2.0 equiv), MeOH, THF, −10 °C, 12 h; (ii) I$_2$ (1.05 equiv), CH$_2$Cl$_2$, 0 °C, 5 min, **20c**: 80% from **35**; **20d**: 67% from **36**; **20e**: 37% from **37**; **20f**: 97% from **38**; **20g**: 58% from **39**; (d) (i) HCl(g), CHCl$_3$, 0 °C, 1 h, 69%; (ii) MOMCl (1.2 equiv), NaH (1.2 equiv), THF, 0 °C, 1 h, 50%. TrCl = triphenylmethyl chloride; 4-DMAP = 4-(dimethylamino)pyridine; MOMCl = chloromethyl methyl ether.

Figure 7 illustrates the synthesis of epothilone analogues **8–14**. *Reagents and conditions*: (a) CrCl$_2$ (10 equiv), NiCl$_2$ (0.2 equiv), 4-*t*-butylpyridine (30 equiv), 20 (3.0 equiv), DMSO, 25 °C, overnight; (b) TBAF (4.0 equiv), THF, 0 °C, 1 h; then 25 °C, 1 h; (c) Et$_3$N (6.0 equiv), 2,4,6-trichlorobenzoylchloride (2.4 equiv), **41** or **42**, THF, 0 °C, 1 h; then 4-DMAP (2.2 equiv), toluene, 75 °C, 3 h; (d) 20 v/v% TFA in CH$_2$Cl$_2$, 25 °C, 3 h (except **43d**); (e) Estimated by ^{1}H NMR ; (f) Deprotection of **43d**: TMSBr (10 equiv), 4Å MS, CH$_2$Cl$_2$, −30 °C, 1 h; then 20 v/v% TFA in CH$_2$Cl$_2$, 25 °C, 3 h. TBAF = tetrabutylammonium fluoride; 4-DMAP = 4-(dimethylamino)pyridine; TFA = trifluoroacetic acid; TMSBr = trimethylsilyl bromide; MS = molecular sieves.

Figure 8 illustrates a scheme showing the last step in the synthesis of many of the analogs from the vinyl iodide **15** and the corresponding aromatic stannanes. A Stille-type coupling of **15** with appropriate stannanes was carried out in the presence of PdCl$_2$(MeCN)$_2$, CuI and AsPh$_3$ in DMF at ambient temperature, leading directly to the analogs in the indicated yields. Reagents and conditions: a. PdCl$_2$(MeCN)$_2$ (0.5 eq), CuI (2.0 eq), AsPh$_3$ (1.0 eq), **120a-120d**, **122a-122d**, **123-124** (2.5 eq), DMF, 25 °C, 1-3 h, 41-80%.

Figure 9 illustrates a scheme showing the steps required to synthesize the stannanes used in the scheme in Figure 8. The thiazole compounds (**120a-120d**) were

synthesized from the commercially available 2,4-dibromothiazole (**118**) by reacting the corresponding thiol with NaH in the presence of the dibromothiazole. Coupling of the product with $Me_3SnSnMe_3$ in the presence of $Pd(PPh_3)_4$ in toluene at 100 °C gave the desired products **120a-120d**. Reagents and conditions: a) NaH (3 eq), RSH (3 eq),

5   i-PrOH, 24 h, 70-81%; b) $(Me_3Sn)_2$ (5-10 eq), $Pd(PPh_3)_4$ (5 mol%), toluene, 100 °C, 1-3 h, 71-88%; c) n-BuLi (1.1 eq), ether, -78 °C, 1 h, then n-Bu_3SnCl (1.2 eq), -78 to 25 °C, 1h, 49-62%.

Figure 10 illustrates a scheme showing the synthetic route taken to build the skeleton of the cyclopropyl analogs of epothilone B. Reagents and conditions: (a)

10   Nicolaou, K. C.; et al. *J. Am. Chem. Soc.* **2001**, *123*, 9313 and Jessie, S; Kjell, U. *Tetrahedron* **1994**, *50*, 275; (b) NaH (1.5 eq), BnBr (1.2 eq), DMF, 0 to rt, 12 h, 100%; (c) O_3, CH_2Cl_2, MeOH (4:1), -78 °C, then $NaBH_4$ (3 eq), -78 °C to rt, 1 h, 83%; (d) MsCl (1.3 eq), Et_3N (1.5 eq), DCM, rt, 1 h; (e) NaI (3 eq), acetone, rt, 12 h, 91% (2 steps); (f) LDA (1.4 eq), **25** (1.3 eq), THF, 0 °C, 6 h, then **129**, -98 to -10 °C, 14 h, 87%; (g) MeI, reflux, 3

15   h; (h) 3N HCl:pentane (1:1), rt, 3 h, 91% (2 steps); (i) LDA (2.4 eq), **19** (2.3 eq), THF:ether (1:1), -78 °C, 1 h, then -40 °C, 30 min, then **132** at -78 °C, 5 min, 80%; (j) TBSOTf (1.5 eq), 2,6-lutidine (2 eq), DCM, -20 °C, 1 h; (k) HF•py, pyridine, THF, 0 °C, 8 h, 86% (2 steps); (l) $(COCl)_2$ (1.2 eq), DMSO (2.0 eq), DCM, -78 °C, 5 min, then **135** (1 eq), 20 min, then Et_3N (3 eq), -78 to 0 °C; (m) $NaClO_2$ (5 eq), NaH_2PO_4 (3 eq),

20   2-methyl-2-butene (75 eq), t-BuOH, THF, H_2O, rt, 1 h; (n) 2-(trimethylsilyl)ethanol (4 eq), EDC (1.5 eq), DMAP (0.1 eq), DMF, rt, 12 h, 73% (3 steps); (o) 20% $Pd(OH)_2/C$, H_2, EtOH:EtOAc (1:1), rt, 2 h, 89%; (p) $(COCl)_2$ (1.2 eq), DMSO (2.0 eq), DCM, -78 °C, 5 min, then **137** (1 eq), 20 min, then Et_3N (3 eq), -78 to 0 °C, 99%; (q) $MeOCH_2PPh_3Cl$ (3 eq), n-BuLi (2.8 eq), THF, 0 °C, 1 h, then **138**, -78 to 0 °C, 2 h, 79%; (r) PPTS (10 eq),

25   dioxane:water (9:1), 70 °C, 12 h, 81%.

Figure 11 illustrates a scheme showing the final steps used in the synthesis of cyclopropyl analogs **104** and **106**. Reagents and conditions: (a) $CrCl_2$ (10 eq), $NiCl_2$(0.2 eq), 4-t-BuPy (30 eq), **20a** or **20b** (3 eq), DMSO, 25 °C, 24 h; (b) TBAF (2 eq), THF, rt, 2 h; (c) Et_3N (6 eq), 2,4,6-trichlorobenzoyl chloride (2.4 eq), **141** or **143**, THF, 0 °C, 1 h,

30   then DMAP (2.2 eq), toluene, 75 °C, 3 h; (d) 20% v/v TFA in CH_2Cl_2, rt, 3 h.

Figure 12 illustrates a table with the cytotoxicities of epothilones **104**, **106** and **107-116** against human carcinoma cells and β-tubulin mutant cell lines selected with paclitaxel or epothilone A. The anti-proliferative effects of the tested compounds against the parental 1A9 and the paclitaxel- and epothilone-selected drug resistant clones

35   (PTX10, PTX22 and A8, respectively) were assessed in a 72 h growth inhibition assay

using the SRB (sulforhodamine-B) assay (Skehan, P.; et al. *J. Natl. Cancer. Inst.* **1990**, *82*, 1107–1112.). IC_{50} values for each compound are given in nM and represent the mean of 3 independent experiments ± standard error of the mean. Relative resistance (RR) is calculated as an IC_{50} value for each resistant sub-line divided by that for the

5   parental cell line (1A9). The results for compound **3** are taken from Nicolaou, K. C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432.

Figure 13 illustrates a table with the cytotoxicities (IC_{50}'s in nM) of selected epothilones against the human epidermoid cell lines KB-3 and KB-8511. The antiproliferative effects of the tested compounds were assessed in two human

10   epidermoid cancer cell lines, including a parent cell line (KB-31) and a Taxol™-resistant (due to Pgp-overexpression) cell line (KB-8511). The results for Epo B and **3** were taken from Nicolaou, K. C.; et al. *Tetrahedron* **2002**, *58*, 6413–6432.

Figure 14 illustrates a table disclosing the cytotoxicity of epothilones **1** through **14** and paclitaxel against 1A9 human ovarian carcinoma cells and β-tubulin mutant cell lines

15   selected with paclitaxel or epothilone A. The anti-proliferative effects of the tested compounds against the parental 1A9 and the paclitaxel- and epothilone-selected drug-resistant clones (PTX10, PTX22 and A8, respectively) were assessed in a 72 h growth inhibition assay using the SRB (sulforhodamine-B) assay (Skehan, P.; et al. *J. Natl. Cancer Inst.* **1990**, *82*, 1107-1112). IC_{50} values for each compound are given in nM

20   and represent the mean of 3-9 independent experiments ± standard error of the mean. Relative resistance (RR) is calculated as an IC_{50} value for each resistant sub-line divided by that for the parental cell line (1A9). CP = cyclopropyl; py = 5-methylpyridine side chain; pyOH = 5-hydroxymethylpyridine side chain; 5tmpy = 5-thiomethylpyridine side chain; 6tmpy = 6-thiomethylpyridine side chain; tmt = 2-thiomethyl thiazole side chain.

25   Figure 15 illustrates a table disclosing the tubulin polymerization potency and cytotoxicity of epothilones **1–8**, **10–14**, and paclitaxel against human epidermoid cancer cell lines. (a) The extent of porcine tubulin polymerization (TP) by 4 µM compound was quantified relative to the effect of 25 µM epothilone B (which was defined as 100%) as described (Nicolaou, K. C.; et al. *Chem. Biol.* **2000**, 7, 593-599). (b) Drug concentration

30   required for maximal inhibition of cell growth (IC_{50} values given in nM) was assessed after a 96 hour drug exposure by quantification of cell mass using a protein dye method as described (Meyer, T.; et al. *Int. J. Cancer* **1989**, *43*, 851-856). KB-31: epidermoid Taxol®-sensitive cells, KB-8511: epidermoid Taxol®-resistant cells (due to Pgp overexpression). Relative resistance (RR) was calculated by dividing the IC_{50} value for

35   the resistant cell line by that of the sensitive cell line. (c) Data from ref. 3 (%TP values

for Taxol®, Epo A and Epo B were 49, 69 and 90, respectively). CP = cyclopropyl; py = 5-methylpyridine side chain; pyOH = 5-hydroxymethylpyridine side chain; 5tmpy = 5-thiomethylpyridine side chain; 6tmpy = 6-thiomethylpyridine side chain; tmt = 2-thiomethyl thiazole side chain.

5   Figure 16 illustrates a table disclosing binding affinities of epothilone analogues to the taxoid binding site of microtubules.   (a) The binding of the different ligands to the taxoid site of microtubules was measured by the displacement of a fluorescent Taxol® derivative (Flutax-2) from its binding site (Figure 2) (Díaz, J. F.; et al. *J. Biol. Chem.* **2000**, *275*, 26265-26276). The Flutax-2 displacement isotherm of each ligand was

10   measured at least twice with a fluorescence polarization microplate reader in a modified procedure from the previous report (Andreu, J. M.; Barasoain, I. *Biochemistry* **2001**, *40*, 11975-11984). Cross-linked stabilized microtubules which had been stored under liquid nitrogen were employed. The binding constant of the reference ligand Flutax-2 was measured by centrifugation and fluorescence

15   anisotropy, at each temperature (Díaz, J. F.; et al. *J. Biol. Chem.* **2000**, *275*, 26265-26276). The resulting reference value was 2.2 (10^7 M^{-1} at 37 °C. (b) The equilibrium dissociation constants (Kd) are given in nM. (c) The standard binding free energy changes (DG$^0_{app}$) are given in kJ mol^{-1}.